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Abstract 
 
This thesis explored women’s and family physicians’ experiences with Bio-identical 
Hormone Therapy (BHT). It aimed to develop a deeper understanding of women’s 
decision-making process in choosing this therapeutic modality, and the influence family 
physicians may have on this process. To capture the phenomenon under study, two 
complementary and sequential qualitative studies were conducted.  The studies involved 
in-depth interviews with women using BHT and family physicians that care for this 
population.  The collective findings of both studies demonstrated the complexity of 
menopause care.  The findings illuminated the major factors involved in women’s BHT 
decision-making process. It also offered important information about the role of the 
family physician and the patient-physician relationship in the journey of women choosing 
to use BHT; in particular, the value placed on family physicians spending adequate time 
exploring women’s experiences, listening to their concerns and being open to the 
independence of their therapeutic choices. 
 
Key Words:  Menopause, BHT, Bio-identical Hormones, Decision-making, Family 
medicine, Patient-Physician Relationship.  
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Chapter 1  
Introduction 
 
Some women have chosen to use Bio-identical Hormone Therapy (BHT) to manage 
menopause, despite considerable controversy concerning the safety and efficacy of this 
therapeutic modality. 1-4  This thesis aimed to gain a deeper understanding of this 
phenomenon through exploring the decision-making process of women who chose to use 
BHT to manage menopause, and the influence of family physicians on this process.  
1.1 The Purpose of the Introductory Chapter 
This chapter will review the history and significance of hormone therapy in menopause, 
introduce the Bio-identical Hormone Therapy (BHT) approach, and outline the 
differences between BHT and conventional hormone therapy. To provide a foundation for 
the qualitative studies in the subsequent chapters, the definitions, prevalence and a 
literature review of both women’s and physicians’ experiences with BHT are highlighted. 
Finally, an overview of the research design used in the qualitative studies is presented.  
1.2  The Significance of Managing Menopause 
 The issue of menopausal health is of significance to society in general because of its 
universality - it affects all women.  Menopause and the peri-menopausal period are 
important transitional chapters in the lives of most women. Natural menopause as defined 
by the World Health Organization (WHO) is 12 months of amenorrhea after the last 
period.5  This is usually determined in retrospect when a woman reports no menses for 
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one year. The average age of menopause is approximately 51 years, with a range of 40 to 
55 years.6  The majority of women in advanced societies can expect to live 30 years 
beyond this point.6  The female population in Canada is aging; in 2010 the 45 to 64 year 
old age group made up about 28% of females, and is expected to increase over time.7  
Although menopause is a natural process, it may be a time where varying degrees of 
psychological and physical symptoms are experienced. Hot flashing, and its 
accompanying symptoms including sweating, palpitations, apprehension, and anxiety, 
affect 60-80% of women entering menopause.8   Although most menopausal women 
(60%) experience hot flashes for less than 7 years, up to 15% report that hot flashes 
persist for 15 years or more.9 Vasomotor symptoms (i.e., hot flashes and night sweats) 
contribute to the woman’s discomfort, and can have considerable adverse effects on her 
quality of life (QOL), which can result in a requirement for medical management.10  
Multiple therapeutic options are available to help manage menopause including: lifestyle 
modification, diet, exercise, herbal therapies, antidepressants and hormonal therapy; these 
have varying success.8  Hormone therapy has been shown to be a superior therapeutic 
agent in relieving vasomotor symptoms and their potential consequences (e.g., diminished 
sleep quality, irritability, and reduced QOL). 11-14   
1.3 History of Hormone Therapy in Menopause 
Hormone Therapy (HT) also known as Hormone Replacement Therapy (HRT) is a 
medication that utilizes hormones, usually estrogen and progestin (a synthetic form of 
progesterone), in the management of menopause.15  The estrogen (estradiol, estradiol 17β, 
or conjugated equine estrogen) can be oral or transdermal and the progestin can be oral, 
transdermal, or delivered via an intrauterine device. 8 
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In the 1990s and up until early 2002, women were routinely prescribed HRT as short-
term therapy to help relieve symptoms associated with menopause, as well as a long-term 
therapy for prevention of coronary heart disease (CHD) and osteoporosis.16, 17  It was 
estimated in the 1990s that more than one third of postmenopausal women aged 50 to 74 
years were taking HRT.18   
Clinical practice patterns changed dramatically after the publication of the Women’s 
Health Initiative (WHI) in 2002, a landmark randomised control trial of HRT that aimed 
to see if the rate of CHD and other events was lower in women who used HRT compared 
to placebo.19 The WHI study showed an increase in the risks of venous 
thromboembolism, cardiovascular disease, stroke and breast cancer with combined 
estrogen/progestin therapy.19, 20  Overall HRT prescriptions decreased by around 38 
percent in the first year after the WHI was published.21, 22 The findings of the WHI were 
also widely publicized in the popular press, producing immediate and major impacts on 
women’s use of HRT.21, 23 It has been estimated that up to 70% of women taking HRT 
stopped within the first year of publication, and 26% reported losing trust in medical 
recommendations in general.24, 25  
More recent publications have criticized the wide public release of the WHI findings, and 
have questioned the interpretation and generalizability of its findings.26-28  Many newer 
studies, as well as secondary analyses of the WHI, propose a re-evaluation of the WHI’s 
initial findings.26, 29, 30   The age of women when they present for menopause care, the 
timing of initiating HRT, as well as type and route of hormones have been proposed as 
contributing factors to cardiovascular and breast cancer  risk. 26, 29-32   As a result, 
hormone therapy prescribing practices have shifted again.  Currently there is an emphasis 
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on lifestyle choices for health promotion and disease prevention; reserving hormonal 
therapy for symptomatic women. 8   
Even though at present multiple menopause societies, including The Society of 
Obstetricians and Gynaecologists of Canada (SOGC) and the North American Menopause 
Society (NAMS), have supported the use of HRT for the management of symptomatic 
menopausal women,8, 33  there still remains much uncertainty among women and their 
health care providers about the safety of HRT.31, 34  As a result, some women have chosen 
to use “bio-identical hormonal therapy (BHT)” or “natural hormones” as an alternative to 
conventional hormone preparations in the belief that they are safer. 4, 35, 36 
 
1.4 Terms and Definitions 
One area of confusion in clinical practice is with the use of the term “bio-identical”. It has 
been used to refer to many commercially available pharmaceutical hormone therapy 
products containing hormones that are chemically identical to the hormones produced 
naturally by women such as 17β-estradiol or progesterone.13  However, the term is also 
most often used to describe custom-made hormone formulations (called Bio-identical 
hormone therapy, or BHT) that are compounded for an individual according to a 
healthcare provider’s prescription.13  The hormones most commonly compounded are 
estradiol, estrone, estriol and progesterone.1-3   In this thesis the term BHT will refer to the 
latter definition. Thus, conventional hormone therapy or HRT will refer to all 
commercially available hormone products, regardless of how well their hormone 
composition resembles naturally occurring hormones, and will include all routes of 
hormone use. 
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1.5 Differences between BHT and HRT 
In addition to the difference in how BHT is made compared to HRT (i.e. pharmacy 
compounded vs. commercially manufactured), there is a difference in the philosophy of 
care and the rational for prescribing specific hormones.3, 37-39 A good example is the role 
of progestogens (i.e. natural progesterone and synthetic progestin) in hormone therapy.  
Currently the primary menopause-related indication for progestogen or progestin use in 
HRT is to counteract the increased risk of endometrial cancer from systemic estrogen 
use.8  The North American Menopause Society recommends that all women with an intact 
uterus who use systemic estrogen should also be prescribed adequate progestogen, while 
women without a uterus should not be prescribed a progestogen.13  
On the other hand, BHT prescribers believe progestogen, and specifically progesterone, 
has a major role in relieving menopausal symptoms.3, 37-40  The theory of “estrogen 
dominance” as a result of the more rapid decline of progesterone compared to estrogen41 
is thought by BHT providers to contribute to menopausal symptoms.40  Thus, BHT 
practice would involve prescribing hormone components (estrogen and progesterone) 
based on the assessment of the women’s presenting symptoms and a measurement of 
salivary or blood hormone levels.38, 39 
There is, however, very little published information about the use of BHT, their safety or 
their efficacy.  The International Menopause Society (IMS) and NAMS do not endorse 
their use.33, 42  NAMS also warns against possible increased risks to the women using 
these products since:  they have not been tested for efficacy or safety; safety information 
is not consistently provided to women along with their prescription, as is required with 
commercially available HT; and batch standardization and purity may be uncertain.33  
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Expense is also an issue, as many custom compounded preparations are not covered by 
medical insurance, resulting in higher costs to the patient.33 In addition, there appears to 
be concern that the terms “bio-identical” and “natural” may be misleading to women, 
suggesting that they are safer than HRT and influencing women’s decisions to use them.4, 
36, 43, 44
 
1.6 Prevalence of BHT Use 
Data on the extent of BHT use in the population are scarce; one study estimates the 
prevalence of compounded BHT use to be about 20% among menopausal women seeking 
care at an academic women’s health centre in the USA.35 Alternatively, the prevalence of 
complementary and alternative medicine (CAM) use among menopausal and peri-
menopausal women ranges from 50%-75% in North America and the UK,45-48 and one 
estimate suggests 95% of women would try alternative therapies before considering 
HRT.49 Since CAM is an overarching term that includes many different therapeutic 
modalities and most studies did not specifically exclude BHT from their reports on CAM 
prevalence, the extent of BHT use may be higher than predicted. 
1.7 Literature Review  
There are numerous publications regarding BHT; however, the majority are review 
articles and physicians’ opinions about the overall BHT approach. Topics include: 
differences and similarities to HRT; discussions on safety and efficacy; and concerns 
about unsupported therapeutic claims.1, 2, 4, 44, 50-53  There is a scarcity of original studies 
that examine the BHT approach. A few studies were identified that directly explored 
patients’ and health care providers’ experiences and views of BHT, these are described 
below. 
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1.7.1 Women’s Perspective on BHT 
Only four studies reported on women’s BHT experiences. Of these, two described 
positive experiences - the restoration of health and alleviation of menopausal symptoms 
for women taking BHT.35, 54 One qualitative study focused on women’s ability to access 
BHT and the factors which either impeded or facilitated that access.55 Another cross 
sectional study looked into women’s beliefs and understanding about the term “bio-
identical”.36 No studies were found which directly explored women’s decision-making 
process to use BHT. 
1.7.2 Physicians’ Perspective on BHT 
No studies were found that examined family physicians’ perspectives regarding BHT, 
their experiences caring for women on this therapeutic modality, or their role in women’s 
BHT decision making process. However, a cross sectional study of pharmacists found 
that those who compounded BHT were more likely to believe in BHT safety, and have 
greater confidence with this therapeutic modality.56 
1.8 Thesis Purpose 
Although researchers have explored women’s decision-making process, beliefs and 
attitudes regarding hormone replacement therapy in general,34, 57-60  There remain many 
unexplored questions related to  women’s BHT decision-making process.   There are also 
many questions regarding the role a family physician may play in that process and how 
the patient-doctor relationship may be affected by patients’ decisions to use BHT. Given 
the lack of literature, an appropriate starting point is to begin by exploring the journey of 
women in acquiring BHT, and their reasons for using it. Secondly, it is important to 
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explore family physicians’ experiences, perceptions, and attitudes toward this treatment 
modality.  This thesis was designed to address these objectives.  
1.9 Thesis Design 
Two qualitative studies using a phenomenological approach were conducted in this thesis. 
It was felt that exploring women’s and family physicians’ BHT experiences separately   
would provide a deeper understanding of each groups individual, and unique experience 
of the phenomenon, 61 and would allow for a more thorough account of their lived 
experience. 62  This specific feature of phenomenology is valuable as it supports a fresh 
perspective absent from preconceived concepts of BHT.  The studies involved in-depth 
interviews with women using BHT and family physicians that care for this population.  
The sample size, as with most qualitative inquiry, is not guided by numerical calculations, 
such as statistical significance or statistical power, but rather is guided by researcher 
judgments about the sufficiency of the information gathered.63 An adequate sample size is 
one that permits deep, case-oriented analysis and rich understanding of an experience that 
is a hallmark of all qualitative inquiry.64  Thus data gathering in both studies occurred 
until “theme saturation” was achieved. That is, when no new themes were seen to emerge 
with further interviews.63   
With respect to constructing the interview guide, Thomas and Pollio suggest that 
interviewers must unlearn how they typically ask questions, to help draw out rich, 
descriptive phenomenological responses from the participants.65  They state that “the 
phenomenological question is not designed to elicit a theoretical explanation or statement; 
hence, ‘why questions’ which lead individuals from description to theory are avoided”.65 
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They propose that using ‘what’ questions helps the researcher elicit more detail-oriented 
accounts of the participant’s experience.65  Moustakas also describes two broad, general 
questions: What have you experienced in terms of the phenomenon? What contexts or 
situations have typically influenced or affected your experiences of the phenomenon? 
These questions focus attention on gathering data that will lead to a textual description 
and a structural description of the participants' experiences, and ultimately provide an 
understanding of the common experiences of the participants.61, 66  These 
recommendations were used to inform the design of the interview guide in both studies. 
In phenomenological inquiry, multiple sources of data are preferred.61, 64  In an attempt to 
have a better understanding of participants’ experiences it is of value to consider both 
their verbal descriptions, as well as their physical responses to questions.   Lived 
experiences are also embodied experiences and people relate to the world with and 
through their bodies. 64  Van Manen considered embodied experiences to be an important 
component of phenomenological reflection and a key element in understanding the lived 
experience.67  Thus, field notes were recorded during, and immediately following each 
interview. They involved observations on, bodily gestures, facial expressions, recoiling, 
reaching out, sighs, and emotional responses.  
In phenomenological research the concept of “bracketing” or “epoche” -  in which 
investigators set aside their experiences, as much as possible, to take a fresh perspective 
toward the phenomenon under examination - is of significance.61  It is an intellectual 
activity, where one tries to put aside theories, knowledge and assumptions about a 
phenomenon.65  It is an approach that is deemed to be an essential component of the 
phenomenological method.65-67 Moustakas states that merely the energy, attention and 
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work involved in reflection and self-dialogue significantly reduces the influence of 
preconceived thoughts, judgments and biases.66 Reflexivity can be defined as “the process 
of continually reflecting upon our interpretations of both our experience and the 
phenomena being studied so as to move beyond the partiality of our previous 
understandings and our investment in particular research outcomes”. 68   Thus the 
intellectual process of reflexivity involved:  thoughts on historical experiences, values and 
pre-understandings of BHT.  
1.10 Thesis Structure 
This thesis explored, through phenomenological qualitative designs, women’s and family 
physicians’ experiences with BHT. It aimed to develop a deeper understanding of 
women’s decision-making process in choosing this therapeutic modality, and the 
influence family physicians may have on this process.  
The current chapter presented a summary of the use of hormone therapy in managing 
menopause, an explanation of the terminology used in hormone therapy, and the 
differences between BHT and conventional hormone therapy. The chapter also provided a 
review of the literature pertaining to women’s use of BHT to manage menopause, and the 
perceptions of family physicians pertaining to this treatment.  
Chapter Two reports on a qualitative study that explored how women seeking menopause 
care reached a decision to use BHT.  The women experienced significant distress in their 
menopause transition and desperation for symptom relief, which lead to their discovery 
and trial of BHT. Ultimately, the women experienced restitution and enhanced wellbeing 
while taking BHT.  However, their healing journey was experienced simultaneously with 
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frustration and disappointment in the medical community’s lack of support and 
acceptance of their treatment choice.  
Chapter Three presents a second qualitative study that examined the experiences of 
family physicians caring for patients who were taking BHT.   The family physicians 
demonstrated awareness of the delicate nature of the menopausal transition for women, 
and their role in helping overcome women’s fears and apprehensions as well as mitigating 
their symptoms.  They described concerns about BHT safety and challenges in reaching a 
balance between their patients’ wishes to use BHT and standard practice.   
Chapter Four integrates the findings from chapters two and three, and discusses the 
shared themes that emerged. In addition, specific policy suggestions are made regarding 
the journeys and decision-making process of women taking BHT. 
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Chapter 2  
Bio-Identical Hormone Therapy: Understanding Women’s Decision-
Making Process 
 
Menopause and the peri-menopausal period are significant transitional chapters in the 
lives of most women.  The average age of menopause (i.e., cessation of menses) is 
approximately 51 years, with a range of 40 to 55 years.1  The majority of women in 
advanced societies can expect to live 30 years beyond this point.1 
 Generally menopause is associated with varying degrees of psychological and physical 
symptoms.  Hot flashing, and its accompanying symptoms including sweating, 
palpitations, apprehension, and anxiety, affect 60-80% of women entering menopause.2   
Although most menopausal women (60%) experience hot flashes for less than 7 years, up 
to 15% report that hot flashes persist for 15 years or more.3 These symptoms contribute to 
the woman’s discomfort, inconvenience, and distress, particularly when these episodes 
occur very frequently.  
In the past, women were routinely prescribed hormone therapy to help relieve symptoms 
associated with menopause, as well as for prevention of coronary heart disease and 
osteoporosis.4   Clinical practice patterns changed dramatically after the publication of the 
Women’s Health Initiative (WHI), a landmark study that indicated an increase in the risks 
of venous thromboembolism, cardiovascular disease, stroke, and breast cancer with 
combined estrogen/progestin therapy.5, 6 In the United States the number of annual 
postmenopausal hormone therapy prescriptions decreased by 38 percent in the first year 
after the WHI publication in July 2002.7 The extensive media coverage of the WHI 
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findings evoked significant discussion, controversy, and concern among women and their 
health care providers about how best to deal with their symptoms.8, 9  Some women have 
chosen to use bio-identical hormonal therapy (BHT) as an alternative to conventional 
hormone preparations.10 The "bio-identical" approach generally refers to the prescribing 
of individualized doses of hormones that are delivered in pharmacy compounded creams 
and pills. The hormones most commonly compounded are estradiol, estrone, estriol and 
progesterone.11-13  
There is, however, very little published information about the use of bio-identical 
hormones, their safety, or their efficacy.  Most Menopause Societies do not endorse their 
use.14, 15  Further, there appears to be concern that the terms “bio-identical” and “natural” 
may be misleading to women, suggesting that they are safer than HRT and influencing 
women’s decisions to use them. 10, 16-18 Beliefs that BHT are safer than HRT likely plays a 
significant role in women’s selection of hormone therapy. Although researchers have 
explored women’s decision-making process, beliefs and attitudes regarding hormone 
replacement therapy in general,8, 19-22 there is little known about the decision-making 
employed by women who use BHT.  Thus, studying women’s reasons and journeys to 
acquiring BHT, as well as their experience using it, is an initial step toward addressing 
this gap.  
2.1 Purpose 
This study aimed to explore: 1) menopausal women’s experiences accessing and using 
BHT; 2) their decision-making process in choosing this therapeutic modality; and 3) how 
the patient-physician relationship may be affected by that decision.  
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2.2 Methodology 
2.2.1 Study Design 
A phenomenological qualitative study utilizing in-depth interviews of women on BHT 
was used. This research framework provides a deeper understanding of a phenomenon (in 
this case using BHT) as experienced by several individuals. 23  The basic principle of this 
design is to reduce individual experiences with a phenomenon to a description of the 
universal essence of the experience. 23 This description consists of “what” they 
experienced and “how” they experienced it. 24 This understanding of the essence of 
menopausal women’s BHT experience may be valuable in directing suitable menopause- 
related counselling, and informing practices that enhance the therapeutic patient-
physician relationship.  
2.2.2 Recruitment and Sampling      
It is essential in phenomenological approaches that all participants have experience of the 
phenomenon being studied 23 Thus, participants who would be able to contribute to data 
that was in-depth and information rich were recruited. 25  Women attending a BHT clinic 
in London, Ontario were recruited for the study.  Potential participants (N=200) were 
identified through the clinic’s records by administrative staff and were mailed a letter 
(Appendix I), which described the study and invited them to participate. Women (n = 35) 
who responded to the letter were screened using a telephone interview to insure they 
experienced the phenomena of  taking BHT for menopause management and met the 
following study inclusion criteria:  (a) women aged 40 or older (b) actively taking BHT.  
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The exclusion criteria included: (a) BHT post breast cancer prophylactic surgery; (b) 
history of premature ovarian failure and menopause before age 40 years; (c) BHT post 
chemotherapy and or radiation therapy; (d) history of breast and/or gynaecological 
malignancy. Throughout the process of recruitment particular attention was paid to the 
following participant characteristics: age; menopausal status (i.e., peri-menopausal or 
post-menopausal); and prior history of HRT use. This was done in an effort to attain a 
maximum variation sample to represent diverse individuals and insure multiple 
perspectives about the phenomenon. 23, 25 
2.2.3 Data Collection 
In-depth interviews were conducted, using a semi-structured interview guide (Appendix 
II) between May to August 2012, at either the BHT clinic, Western University, or the 
participant’s home; two interviews were conducted by telephone.  Interview questions 
were structured around three main areas: (a) describing the menopausal transition; (b) 
describing the experience of attaining and using BHT; and, (c) understanding 
participant’s views of the family physician’s role.   However, each interview was also 
guided by the emerging dialogue, and the interview guide was adapted as new 
information emerged from the data analyses. Consent (Appendix III) was obtained before 
all interviews.  Interviews, which lasted approximately 45-60 minutes, were audio-
recorded and transcribed verbatim. Field notes and reflexive journaling 23, 26, 27were 
completed during and immediately following each interview.  Participants received a $10 
gift card in appreciation for participating. The study was approved by Western 
University’s Ethics Board (Appendix VII).   
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2.2.4 Data Analysis 
Analysis of all interview transcripts and field notes occurred through an interpretive and 
iterative process that included the following; (1) reading and familiarization with each 
transcript’s overall descriptive account; (2) grouping recurring words and significant 
statements into a coding template that was organized in a similar manner to the interview 
guide;  (3) generating  units of information called “themes”23, 27 and continually 
expanding, and revising them as new themes emerged throughout the data collection and 
analysis; (4)  using diagrams to compare themes across  participants; (5) collapsing 
smaller subthemes within larger thematic units; (6)  identifying  exemplar phrases that  
captured the themes; (7) producing the manuscript.  Data analysis occurred concurrently 
with data collection and continued until theme saturation was achieved (i.e., when no new 
themes were seen to emerge with further interviews).25 Initially the researchers (LW, GR, 
AT∗ ) individually and independently read each verbatim transcript. The researchers 
subsequently met on a regular basis to compare and combine their independent analysis, 
and to synthesize the data in a comprehensive and agreed upon description of the essence 
of the phenomenon. Techniques used to promote trustworthiness and credibility of the 
data involved: 1) purposeful screening to ensure all participants experienced the 
phenomenon; 2) maximum variant sampling to enhance the capturing of varying 
perspectives of experiencing the phenomenon; 3)  audio-recording interviews, verbatim 
                                                          
 
 
 
∗
 LW: Lemmese Alwatban , GR: Graham Reid, AT: Amanda Terry 
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transcribing and detailed field notes to maintain methodological rigor; 4) team analysis 
and reflexive journaling to maximize researcher transparency; 5) constant referring back 
to the data for verification of emerging themes  to ensure applicability of the analysis to 
the context of events.25, 28 
2.3 Final Sample and Demographics 
After respondents were screened using a telephone interview, a total of 32 women met the 
study criteria.   Participants were selected for interviews based on maintaining a variation 
in their age; menopausal status (i.e., peri-menopausal or post-menopausal); and prior 
history of HRT.   Maximum variation and theme saturation were achieved by the twelfth 
interview.  Only data for the 12 participants are described. Participants ranged in age from 
54 to 68 years of age (mean = 56 years). The majority (n=10) were post-menopausal (i.e. 
had not had a period for 1 year or more) with a mean of 10 years since their last period 
(range 2-25 years); two women were peri-menopausal. Few (n=5) women had 
hysterectomies. All participants were Caucasian. The majority (67%) were married; 33% 
were divorced or separated. Two thirds of participants had a college degree or higher 
level of education; the remaining one third had completed high school.  The annual 
income of most (75%) participants was $40,000 CAD or higher; 25% had an annual 
income of $20,000-39,999 CAD.  
Half of the participants had taken HRT in the past; only two had made a direct transition 
from their HRT therapy to BHT.  Women in this study were taking BHT for a mean of 
2.5 years, with a range between 3 months and 8 years. Six women were taking a 
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combination of three hormones (testosterone, estrogen and progesterone), one was taking 
progesterone only, and the remainder were taking an estrogen, progesterone combination.  
2.4 Findings 
 
Analysis of the data revealed five inter-linked themes which describe the essence of the 
women’s BHT journeys:  a) transition into menopause; b) quest for symptom relief and 
restitution; c) decision to use BHT; d) experience using  BHT; and, e) the patient-
physician relationship through the journey. Participants reported experiencing distress 
during the menopause transition and described chaotic accounts of suffering, confusion, 
helplessness and isolation, resulting in a sense of desperation that fuelled their incessant 
quest for relief. They described an experience of restored well-being and a regained sense 
of normality on BHT. Although their healing journey was one of victory, it was 
experienced simultaneously with frustration and disappointment in the medical 
community’s lack of support and acceptance of their treatment decision. 
2.4.1 Theme 1: The Transition into Menopause (Menopausal Turmoil) 
The transition into menopause was a very difficult time for most of the women in the 
study. The impression of chaos and turmoil were predominant in the findings, and 
appeared to have four elements: suffering, confusion, helplessness and isolation.  These 
elements were not isolated to the menopausal transitional period alone, but were also 
inter-woven throughout the women’s journey to their restored well-being. They 
contributed to an underlying current of desperation that was the catalyst to their relentless 
search for relief.   
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2.4.1.1 Suffering 
The participants suffered as a result of unremitting symptoms and their consequent social 
implications. They described their menopause transition as being “horrible” and 
“unsettling” or even feeling “under assault”.   Most women felt their symptoms 
overshadowed all other aspects of their lives:  
You can’t be prepared for the cloud; it’s like a gray cloud. You’re living under a 
gray cloud and even though maybe the sun’s shining on days, you couldn’t get 
excited about it ... it really zaps you of your spirit! 
All of the participants reported experiencing similar clusters of physical and emotional 
symptoms.  The most commonly mentioned and disturbing symptoms were hot flashes, 
night sweats and sleep disturbance: 
The hot flashes were just horrendous!  I would be awake 10 times every night 
with drenching night sweats, drenching to the point I have to change my pajamas 
10 times every night. I had to blow dry my hair two or three times every night 
because my hair was soaked ... It got to the point that I thought I was going to go 
nuts!  
In terms of emotional symptoms participants told stories reflecting how difficult it was 
for them to cope with day to day life: 
I felt at times that I was actually dying. I would really say that.  I really felt that 
poorly about myself.  I think I got depressed because I wasn’t sleeping.  When 
you’re up every hour through the night, I was dragging through the day. I wasn’t a 
nice person to be around.  I just didn’t feel well.  I didn’t feel well at all. 
The suffering of the participants in this study was not only related to their physical and 
emotional symptoms, but also by the impact they felt their condition had on their family 
and their vocation.  The majority of participants expressed feelings of guilt towards 
family members who endured the transition alongside them. They also contemplated 
making major changes in their work load to accommodate menopause “certainly ending 
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my job and thinking I’m just going to have to take it easy, I can’t keep working and 
[should] not take on any kind of anything”.   
2.4.1.2 Confusion 
Participants’ expressed confusion as part of their menopause experience.  Many women 
were not sure if their symptoms were menopausal in origin, or if they were a result of life 
stressors, or another medical condition:   
 I also went into a deep depression, and  that’s where it got confusing for me, I 
didn’t know if I was having mood swings because of the menopause or the 
depression, or ... because I was raising a teenage daughter by myself, or ... because 
I’m still going through the divorce.   
Even though women in this study sought medical help from their family physicians, many 
felt they did not receive a clear diagnosis of menopause, which added to their confusion -  
“I don’t know if I’m even there yet. Nobody’s ever came out and said, “Okay, you’re now 
full blown menopausal.”   
2.4.1.3 Helplessness 
Helplessness was a predominant aspect in the participant’s transition into menopause.  
“You can’t help yourself. You feel really helpless!”  This was primarily rooted in their 
sense of losing control as a result of unmanageable symptoms. The trial of multiple failed 
remedies contributed to these feelings:  
 I tried wild yam cream ... Primrose oil ... many pills... I didn’t find they helped at 
all ... Diet was the big thing too. You know, eat healthy and exercise and you 
won’t feel a thing.  Well, that’s not true! 
 If they made it, I tried it! ... The doctor put me on the pill and that was bad, bad, 
bad.  I ended up with yeast infections.  He put me on premarin, and that caused 
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yeast infections ... He put me on depression medication and I didn’t like it at all [I 
felt like a] Zombie. 
On the other hand, many participants reported being urged by health care providers to 
tolerate their symptoms under the premise that menopause was a natural process that did 
not require intervention. Those encounters appeared to have a discouraging effect on the 
women and exacerbated their sense of helplessness: 
 What made [menopause] really awful was that I was trying to get help and I just 
felt like nobody was helping me! I’m going to these doctors and I’m thinking 
shouldn’t they be able to help me?... if he can’t help me then I need to go 
somewhere that can ... it gets frustrating. 
 
2.4.1.4 Isolation 
The majority of participants spoke of a great sense of isolation as illustrated by the 
following quotes:   
 I felt so removed from everybody that I thought I was looking through a screened 
window, looking down at everybody else as they were carrying on their day. 
  I sort of retreated from everybody because I was angry inside and not feeling 
well, but nobody seemed to really understand what I was going through.  So rather 
than getting in a lot of conflict, I just sort of withdrew from everybody.  
[Menopause] made it very difficult for me to work.  It made it difficult to get 
along with colleagues.  It made it difficult to get along with my family, my 
children.  It gave me a sense basically that I didn’t give a shit about anything! I 
just wanted to socially withdraw, to turtle.  
Feelings of isolation were compounded by a lack of understanding from family and 
friends and a lack of sympathy from medical professionals:  
This was really important that I was going through and it didn’t get the attention 
that it needed.  He [family physician] minimized it!  
 
2.4.2 Theme 2: The Quest for Relief 
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A predominant subtheme that emerged was that of desperation. It appeared to surface 
from the relentless symptoms and resulting turmoil women were experiencing during 
their menopausal transition “I was at that point I was ready to try anything ... I was 
grasping at straws”.   Desperation was the primary driver behind the participants’ 
unremitting search for relief, and their willingness to experiment with different remedies. 
“I needed to find something to solve my problems; I was on a quest to find something that 
works for me.” The participants’ active search can be divided into three distinct steps: an 
initial general exploration of any therapy that may be beneficial, the discovery of BHT as 
a therapeutic option, and finally a focused search for a BHT provider (see figure1).
 
Figure 1: Women’s Menopausal Journeys  
 
2.4.2.1 First Step, General Search 
Although the search for “anything that works” was pervasive among participants, two 
clearly distinct groups emerged: women who were willing to try anything, including 
HRT, and women who were interested in only trying any natural remedy.   
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Participants who sought natural treatment options had some degree of aversion to 
prescriptive drugs and conventional medicine “I divorced the western conventional 
medicine theory with a number of things years ago.” This group reported being 
principally concerned about the safety of the pharmaceutical HRT as a treatment 
modality:  
 ... because of all the stories I’ve heard on the pharmaceuticals, I chose not to do 
them and to try anything that’s natural, because I feel a little bit safer with natural 
products. 
Participants who were open to HRT felt their family physician’s support and 
encouragement was an important factor in persuading their decision to try HRT.  Women 
in this group commonly felt significant symptom relief and would have been content 
continuing on HRT.  Many women in this group described being urged by their family 
physicians to discontinue HRT after the publication of the women’s health initiative 
(WHI) study5, 6:   
I tried to go off [HRT] for a while ... when [the WHI] study first came out.  So I 
said to doctor [name], “Okay, I’m going to try and go off [HRT].  I went off for 
several months.  I just felt wretched! I mean just awful!  ...  I went back to not 
being able to sleep... [Hot flashes] were every half hour. I persevered for a while 
and then I went back [to my doctor] and said, “Look, this is not working for me!”  
And again, we have the discussion about quality of life as opposed to quantity... so 
I went back on [HRT].  
Regardless of the participants’ management preferences, many experimented with a 
multitude of natural and pharmaceutical therapies including: vitamins, herbal 
supplements, life style changes, diet, oral contraceptive pills, and anti-depressants. Many 
of these therapies were not effective in relieving their symptoms. The repeated failed 
trials of various remedies reinforced the women’s desperation and contributed to the 
sense of chaos in their menopausal transition.  
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2.4.2.2 Second Step, Discovering BHT 
Most participants discovered BHT through word of mouth. The act of other women 
sharing information about BHT with them reassured and encouraged many participants to 
explore this modality: 
 A lot of it I think is word of mouth. When the girls get together and do their chit 
chats you learn so much. Even things that you’re scared to pursue, when you’re 
amongst friends and you talk, it’s easier to learn and find out about things. 
Testimonials and observing friends’ or family member’s symptoms improve while on 
BHT were strong factors in influencing women to try BHT. Yet most participants read up 
on BHT before moving on to the third step of their active quest, a focused search on 
finding a suitable BHT provider.  
2.4.2.3 Third Step, Focused Search  
Once women established that they were going to try BHT they were determined to find a 
suitable practitioner; however this was a challenging process: 
I want to explain to you how difficult it was finding a doctor that would provide 
bio-identical hormones ...  I researched online and the only doctors that I could 
find, one was in [city-X] and one was in [city-Y].  So I decided just [based on] 
traffic, it was better to go to [city-Y] ... You can imagine, you start having some 
issues and you have to go all the way into [city-Y]  
Participants usually identified a suitable BHT practitioner prior to approaching their 
family physician for a referral: 
... I went to my family doctor and I said: You know, I can’t tolerate these 
symptoms anymore ... I went to my family doctor because I want to see doctor 
[BHT provider] and he usually will go ahead and follow through on things that I 
want ... Even though he’s not quite convinced about the seriousness of it, but he 
will do what I ask or request, I guess. 
 
2.4.3 Theme 3: Decision to go on BHT 
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Decision making for the majority of participants was a nonlinear process that 
predominantly occurred during the second and third steps of their quest for symptom 
relief, and involved the following four components:  a) evaluation, b) resolve, c) 
reinforcement, and d) conflict.   
2.4.3.1  Evaluation 
Many participants researched BHT prior to deciding to use it.  Media sources were the 
resources most often used including both written material (i.e. magazines and books) and 
television shows. Books by a popular celebrity promoting BHT were unanimously 
mentioned by women as a very educational source, even though the majority did not 
believe celebrity endorsement was a valid resource:   
...I also read the Suzanne Summers book where she talked about [BHT], and I was 
going “oh my god, that’s me, that’s me right there”.  So I pursued it, and I decided 
to go to my doctor and get a referral.  
Searching for information on the internet was frequent among participants and was 
considered to be a more reliable source than media based references:  
 First I read Suzanne Summers book that was my first step... and then of course 
I’m looking at it like really?  Because she’s a flake as far as I’m [concerned] ... 
then I just looked it up on the internet. 
Another common resource was books by naturopaths or herbalists. Other participants 
relied on medical sources of information.  They turned to their pharmacist and BHT 
practitioners for information. “... The only sources I’ve really used are the pharmacists 
and the [BHT] doctors.”  
2.4.3.2  Resolve    
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The impact of testimonials and word of mouth were powerful forces in influencing the 
decision making process. However, a constellation of internal and external factors also 
had a major role in persuading participants to reach their final decision of going on BHT.  
Those factors included an intermingling of internal beliefs and attitudes about health care, 
that were reinforced by the external information (e.g., books ) they had found on BHT, 
which were further supported by the women’s perceptions of BHT’s safety.  Many 
women in the study appreciated the philosophy of BHT and found it “made sense”. They 
believed that there were no concerns in using BHT, as the source of the hormone 
production was plant based, and also believed it to be more natural as exemplified in the 
following statements:  
What I very much like is the naturopathic sense of it.  I’m not plagued with the 
thoughts, if I may put it that way, plagued with that sense of risk and side effect. 
When I’d heard that these things [BHT] were at least plant based, I thought “Okay 
I’m going to go for that” ... I figure if they can make something that works for me 
and it’s from a plant, it can’t be that bad. 
 I would have taken anything, honestly, to just stop the symptoms. But the idea...  
that these things [BHT]  ... are matching the body and are actually good for the 
body ... I was willing to try that. It sounded better to me than the pharmaceutical, 
just because it seemed natural. 
Even though most participants felt BHT was a reasonably safe treatment option a 
significant number of women voiced their concerns about risks and evaluated their own 
personal histories in determining the suitability of this treatment for them: 
First of all, I don’t have a uterus so there was no problem with the cancer of the 
uterus. And, that was more with the premarin and provera or whatever those were 
called.  I think with estrogen, there’s the concern with breast cancer, and stuff like 
that.  Again, there’s none in my family.  I looked at the risks and I said it was 
definitely worth trying. 
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Others felt that the severity of their symptoms justified taking a risk. “There hasn’t been a 
lot of clinical studies done as far as bio-identical and cancer that I’m aware of ... but my 
benefits outweigh those risks”. But many felt that even though there might be some risk 
with BHT is was far less than conventional HRT. Many women spoke passionately about 
their right to chose: 
I think it’s the same as any woman; you make an informed choice to take the risks 
or not take the risks ... so you make a decision and you think okay “I’m going to 
take those risks. I’m going to take those because I am not going to be miserable” 
... If it’s a choice between being miserable and taking the risk, I’m going to take 
the risk...I don’t believe in misery. 
The hope for symptom control was the main purpose women started BHT: 
I was just hoping that this would help because basically my doctor said there’s not 
a whole lot else out there ... when I found out about this [BHT] I’m like, oh my 
gosh, maybe there is something out there…that can help. 
 
2.4.3.3  Reinforcement 
Starting BHT considerably improved menopausal symptoms for the majority of 
participants.  Symptom improvement was the primary reason for their satisfaction with 
BHT, and a key factor reinforcing their decision to use it: 
Because I had experienced the natural progesterone cream and how well it 
worked,  without any negative side effects, I was willing to try the estrogen and 
testosterone ... without hesitation. 
Many women felt transformed by BHT and statements like “Bio-identicals absolutely 
changed my life, I feel better now than I have in my whole life!” and “It gave me my life 
back ... it saved my life!” were frequently reported.  
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The dramatic symptom response had a resounding effect on the participants’ commitment 
to this treatment modality.  Many women declared   “I wouldn’t be without them”, had 
strong desires to advocate for its general availability, and were empowered to educate 
other women about it. 
For about a year I was telling every woman I knew that you can get some relief ... 
Now that I’m on bio-identical hormone creams, I said, I feel like my old self. 
I would highly recommend [BHT], now that I’ve [been on it], I’m very 
comfortable with them ...  And now after seeing it helping me for the last three 
years, I would highly recommend it.  
   
2.4.3.4  Conflict 
Many participants were conflicted by their thoughts about the long-term safety of being 
on BHT and their fear of symptom recurrence if they discontinued it. As a result, women 
in this study did not have a set plan to stop BHT at a specific point, and were not able to 
project how long they would continue on it.  There was a common belief among 
participants that their BHT practitioner would guide them to the appropriate timing of 
when to consider discontinued BHT use, yet the majority preferred to not think about that 
possibility and had decided to continue on them as long as possible. 
I will stay on it. I’m afraid to go off. I really am!  I’m afraid to go off hormones ... 
I feel that if I go off of bio-identicals, I will have all my symptoms back and that 
scares me ...  So I will stay on it as long as I can. 
Will I stop them soon?  No, not on your life! I said I’m going to give up food 
before I give up my bio-identicals. 
Some women in this study approached this conflict through their intention to periodically 
re-assess its need and safety. 
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... I wish there was maybe another 20 years of research on it. I feel like I’m part of 
the guinea pig group, which is okay.  The alternative of going right off of 
everything doesn’t sound very pleasing ... I’d like to take it five years at a time ... I 
mean if I can stay on them for all of my life and they are said to be safe, I will! 
But because it’s so new, how can they say that really?  So in my mind I’m 
thinking, well, I’ll judge for five years, If everything seems fine and I’m still able 
to do all the things that I want to do….  I figure I’d rather take the chance that 
there are some risks, if there are any risks, than go back to not being able to do 
anything. 
 
2.4.4 Theme 4: The Experience of Being on BHT 
Most of the women in this study experienced a significant reduction in their menopausal 
symptoms while on BHT. They reported dramatic responses with symptom relief that 
appeared to be directed to the women’s own individual and most bothersome complaints:   
I’d have trouble going to sleep, I’d have trouble staying asleep, I’d have trouble 
sleeping in the morning ...  Now I go to bed at night, I fall right to sleep; I stay 
asleep until my alarm goes off in the morning. 
The hot flashes, after a few weeks, were starting to decrease.  It wasn’t like bang 
the first night or anything but within a few weeks, I did notice they started to 
decrease in intensity and severity.  
I was bleeding about every 11, 12 days ...  today, I‘m bleeding once a month 
which is stunning to me, It’s just stunning!   
Women felt their symptom reduction was rapid, and reported a range between 3 days and 
four months to achieve satisfying symptom management. Many were astonished by their 
response and were elated at their restored health. Women talked about regaining a sense 
of normality, “This is the first time I feel normal again”; retrieving their old selves, “I feel 
like I’m back to the person that I was years ago”; and recapturing their womanhood, “It 
just makes me feel like a whole woman again”. Many women described their symptom 
relief as “a weight being lifted”.   
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Within the first month of using [BHT], it’s like a huge cloud gets lifted, fog gets 
lifted.  You can see clearer, you can sleep better everything is better! It’s like 
looking through clean glasses. 
The main drawback reported by most participants was the expense of BHT as it was 
generally not covered by most of their health plans.  Yet, women expressed their intention 
to continue using BHT regardless of cost and expressed frustration that it was not readily 
obtainable: 
 I don’t like the cost of it.  The price is a little bit high, but I’m willing to starve to 
get my bio-identicals! 
It’s covered on my husband’s plan. Maybe one day it won’t be covered on his 
plan, but I’m going to make sure I get it any way. I’m going to factor it into the 
cost of living. 
You know for a lot of women they wouldn’t be able to afford it.  And I think 
that’s unfortunate  ...  because I think it’s an aid to better health and good living.  I 
don’t feel that it should be a luxury!  I think it should be available to people who 
need it. 
In summary, participants’ desperation for menopausal symptom relief was the primary 
driver behind their search for a remedy.  This search reached an end with the discovery of 
BHT and the positive experience using it. Despite the obstacles in obtaining BHT and the 
mixed views on the safety of this modality, participants decided to continue its use and 
declared it to be their ideal therapeutic choice.    
2.4.5 Theme 5: Menopause and the Patient - Physician Relationship 
Exploration of the participants’ reflections on the relationship with their family physician 
throughout their menopausal journey revealed two distinct stages. Stage one, before 
discovering BHT and stage two, after discovering BHT (see figure 2). This section 
describes these themes in detail. 
 37 
 
 
 
Figure 2: Family Physicians Roles throughout the Women’s Menopausal Journeys 
 
2.4.5.1  Stage One, Family Physician (FP) as Life Line 
 This stage encompassed the participants struggle with menopausal symptoms and 
resulting turmoil as well as their relentless search for relief prior to discovering BHT.  
Women during this stage appeared to turn to their family physicians with hope for help 
and support during the hardships of their menopausal transition.  There were three factors 
which emerged and were believed by participants to be pivotal to their health care during 
this life transition, and essential to maintaining a satisfactory relationship with their 
family physicians thereafter. These factors were: (a) the physician’s realization of the 
significance and vulnerability of menopause; (b) anticipating and preparing women for 
possible symptoms during this evolving period; and (c) providing women with 
therapeutic choices and management options. 
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All participants in this study felt that the menopausal transition was a very important time 
in a woman’s life, yet one that did not receive the attention it deserved. “Women are 
being ignored! It’s a great injustice”.  Many women were expecting their family 
physicians to play a central role in helping normalize their experiences and in working 
with them to achieve a healthy transition. 
... There are many big stages [in life] and [menopause] is one of them. I’d like to 
know that my doctor would take great interest in following along with me and 
encouraging the positive or the healthiest side of [this stage].   
Participants believed family physicians should consider the generational change in 
women’s roles as an essential feature in understanding the impact menopause has on 
women today. 
 I think [doctors] should be much better informed about the comfort level of 
women, and the fact that women are not dying after they’ve had their last set of 
children any more. Things have changed, and [doctors] have to look at things very 
differently...They need a more informed approach to the ageing process, the 
comfort level of women, and the fact that women are in the workforce much 
later... than they were years ago. ... Some family physicians still have the view 
that it’s a natural process.  Well maybe it’s a natural process, if you’re going to die 
a few years afterwards. But even then, I don’t think you need to be miserable for 
those few years. I think comfort is very important. 
Participants identified that having a family physician who listened to their concerns was 
vital to building a trusting therapeutic relationship:  
  I tried to talk with my family doctor about my menopausal symptoms, but he sort 
of brushed them off. ...  That was sort of [a] communication barrier ...  I went 
ahead and referred myself to the women’s health clinic ... to see if they could 
provide me with any more information about menopause. 
Part of being heard was being given sufficient time during clinic visits to explore issues, 
and being asked questions which suggested to participants that their physician was 
interested in the impact of menopause on their lives. 
 39 
 
 I really think they need to ask how [you are] feeling, because when it’s happening 
to you, you’re lost! 
On the other hand, many women felt they were being heard by their BHT provider, and 
thus better cared for.  
The gynaecologist and my family doctor wouldn’t even take the time of day to 
talk about menopause or what’s available.  And in this situation, somebody [BHT 
provider] listened to me. That’s a big difference. 
A central feature of a positive patient- physician relationship repeatedly described by 
participants was having a family physician that was compassionate and understanding. It 
was also considered to be a key factor in feeling heard and cared for.  
2.4.5.1.2  Prepare Women for Menopause 
Women in this study took responsibility for their own education related to menopause. 
However, they also emphasised the necessity of family physician-directed education, and 
the role that physicians have in preparing patients for possible symptoms during 
menopause:  
I feel that [family doctors] have a responsibility to provide women with a fairly 
comprehensive description of what happens, what to expect in menopause, what’s 
causing it in menopause, and perhaps, in some cases, even have the husband or 
partner come in at the same time so that everybody knows what’s going on.  
This anticipatory approach to menopausal care was believed by many participants to be 
reassuring with the goal of there being no “surprises”. Women felt such an approach 
would reduce their anxiety in response to new physical and emotional symptoms.  
This approach was also considered to be vital in overcoming communication barriers such 
as embarrassment in bringing up symptoms with male physicians.  Having a male family 
physician was considered by some women to be an obstacle in their menopausal care. 
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This was either due to feelings that a man would not be able to appreciate the significance 
of their symptoms as well as a woman would, or due to the woman’s hesitancy in 
bringing up complaints related to their reproductive system with a male physician. The 
women who did discuss their symptoms with male physicians expected their physicians to 
overcome any gender disadvantages by expanding their medical knowledge of women’s 
health issues. Women also stressed the importance of an enhanced awareness of the 
spectrum of menopause symptoms and its differing impact on women.  
 I think that a family doctor, whether male or female, should be very educated. 
Not just thinking that a woman’s going through menopause, she’s going to have 
irregular periods, hot flashes, brain fog, and night sweats and that’s the same for 
everybody. It’s not the same for everybody ... Not everybody can be put in the 
same mould, everybody’s different.   
In general, women felt it was the physician’s responsibility to initiate the menopause 
conversation.  When asked what physicians could do to better help women going through 
menopause, many participants suggested physicians participate in public and wider 
spread methods of initiating the menopause conversation and education.  For example, 
women suggested that physicians organize seminars, where women could freely talk 
about their menopause journey. Pamphlets and hand outs on menopause were suggested 
by other participants as a method physicians could utilize to open the discussion:   
If [doctors] don’t have time to discuss [menopause], then they should have a hand 
out of some sort that you take it home, you read it ... [and then have] a discussion 
afterwards. 
 
2.4.5.1.3  Provide Therapeutic Options 
The deficiency in therapeutic options offered by family physicians was an additional 
missing factor during stage one (family physician as life line), raised by participants.  
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Many women hoped for a more holistic approach to menopause management that 
involved life style recommendations as well as available pharmaceutical and non-
pharmaceutical remedies. Participants also expected to have an open conversation with 
their family physicians on hormone therapy risks and benefits: 
 What are all the options, what healthy habits can a woman engage in to assist 
with menopausal symptoms, and to alleviate them? ... “Okay you want HRT? 
These are the risks and benefits, based on your family history or based on your 
medical history”... 
 Many women felt their physicians did not ask them enough questions about their 
menopause experience before prescribing a treatment.  On many occasions, the lack of 
symptom exploration resulted in scepticism about the appropriateness of the treatment 
prescribed.  
I don’t really think that I should be put on an anti-depressant. I think we should be 
finding out if these symptoms are menopausal, or if there’s something else 
causing it, before I go on anti-depressants. 
 In addition, participants who were prescribed medications that did not work felt 
discouraged and abandoned by their family physician.  
They need to send you to somebody who they think can help you.  If they feel that 
they can’t, that [HRT] is the only thing that they can do, and if [it] doesn’t help, [then] 
“I’m sorry I can’t help you”. That’s a horrible thing to hear. 
Alternatively, some women felt they were not allowed to make their own choices, due to 
their family physicians fear of HRT risk. Some participants described frustration with 
their family physician’s paternalistic approach.   
Keep up with the information on the research and let your patients know about it, 
but give them the choice after that. Even have them sign a paper saying, “My 
doctor has explained to me the pros and cons and I have chosen this route, even 
though it could be detrimental to my health in the long run.”  I think taking the 
responsibility off that way would be a good thing because I’m sure he’s very 
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responsible and I understand his concerns and his position, but, give the 
responsibility back to the patient who’s made the choice.  
Overall, participants valued discussing their therapeutic options with their family 
physicians and would have liked to explore complementary and alternative therapeutic 
modalities with them. 
I think that [family physicians] should be open to the different avenues that are out 
there for women, not just say ‘Well here’s some HRT’. 
Regardless if the participants’ experiences in the first stage were positive or negative; all 
participants could be described as having transitioned into a second stage, in which they 
used their family physician to access BHT.   
2.4.5.2  Stage Two, Family Physician (FP) as a Stepping Stone 
The next stage in participants’ journeys was characterized by being on a mission to get a 
referral to a BHT provider, or a prescription for BHT. The family physicians’ role was 
quite limited to either facilitating or impeding their ability to get BHT.  The family 
physician was seen as a facilitator if he or she expressed openness to the BHT modality, 
sent a referral to a BHT provider, and supported the woman’s’ decision to use BHT: 
 When I talked to him [participant’s family physician] about what I learned and 
what I need, and I need a referral, I knew what doctor I needed to come to, he was 
more than willing to help me get to that next level.  And anything new that I find 
out or need, he’s very willing to help me get there.  He’s very open.  He’s not one 
to squash anything! 
The women in this study appreciated a non-judgmental acceptance of their choice to try 
BHT. They predominantly valued the openness of the physician to this treatment 
modality – a quality that was considered to be vital to forming and maintaining a 
satisfying patient-physician relationship. Many participants were accepting of their 
physicians’ lack of BHT knowledge and did not consider it to be a major obstacle, as long 
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as the physician was still open to exploring BHT with them, as demonstrated by the 
following participant’s response to the question: “What were you looking for when 
approaching your physician with BHT?”  
I suppose knowledge, to a certain degree ... maybe at times I’ve often felt that 
maybe I’m almost kind of educating them to a small degree. I just I wanted very 
much an acceptance!  I wanted very much an open attitude, an open-mindedness. 
When physicians were not supportive of their patients’ interest in BHT, participants 
thought that the lack of physicians’ BHT knowledge may be a significant factor in their 
discomfort with this modality and an issue that could prevent them from being open to 
talking about it. Family physicians were seen as a barrier to accessing care if they were 
closed to the idea of BHT. 
Maybe this is something that they’re not really open to, that’s the feeling that I 
got. They’re not open.  It was just like, yeah, and a roll of the eyes! ... ... My 
girlfriend’s ... doctor absolutely refuses to write a referral to [ BHT provider’s 
name].  We’re trying to tell her, go to a walk-in clinic. She’s suffering a lot and 
her doctor, who is a woman, says no! ... That’s not fair!  Just because the doctor 
doesn’t believe in it, doesn’t mean that we should have to be prohibited from 
having bio-identicals because our family doctor isn’t on board. 
The significance of the physicians’ openness to BHT was so striking that some women 
continued to be unsatisfied even after their family physician referred them for BHT. Some 
participants felt so strongly about their physician’s openness to alternative treatment 
choices that they chose to end their therapeutic relationship with their physician.   
... I knew I needed to find another family doctor ... there was one who was taking 
new patients.  I filled out the form, and on the form I said I’m very interested in 
bio-identical hormone therapy.  So if you’re not, then I need to find someone else!   
Interestingly, in most cases the family physicians’ role continued to be restricted to 
patients’ non-menopause health care while they were on BHT.  That appeared to be either 
a result of the physician’s withdrawal from that aspect of their patients care or due to the 
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patient’s choice to separate their family physician from their menopause and hormone 
therapy. The latter emerged as a direct effect of negative patient-physician interactions.  
 He’s become a non-entity.  I only go to him for orthotics, nothing usually more 
important than that. I don’t go to him for anything important because this was 
really important that I was going through and I didn’t get the attention that I 
needed.  He minimalized it!  So I went to other people that were more 
understanding.  So now, I don’t waste my time talking to him about it.  I just go to 
the ones that helped me to begin with. 
There were many reports of disjointed health care among participants, with the 
physician’s lack of interest in their hormone therapy as a repeatedly cited reason:  
 I would still go back to her if I felt I had an ear infection or whatever, for 
anything that I would think I need an MD doctor.  But as far as hormones, no!  
That won’t be discussed because she made it quite clear to me she’s not interested 
in helping me in that area at all.  She was very, very definite. 
Women also interpreted the absence of their physician's curiosity about their BHT 
therapy as a disinterest in their general menopause care. In fact, some were upset at the 
loss of their family physicians involvement. 
 He should be interested; he should ask questions ...  He doesn’t even ask me, he 
doesn’t ask me anything about them when I go to see him.  He doesn’t say, “Oh, I 
see you’re on bio-identical hormones.  Are they working for you? Do you think 
about this?  Do you think about that?”  But he does not ask me a thing. 
Thus, having family physicians that were open to BHT and interested in their BHT 
experience made participants feel valued and cared for. 
2.5 Discussion 
This section will discuss five prominent themes with regard to understanding menopausal 
women’s decision and experience using BHT, and the journey that led to that therapeutic 
choice as well as offer family physicians some relevant clinical recommendations.  These 
themes include:  a) the transition into menopause; b) quest for symptom relief and 
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restitution; c) the decision to use BHT; d) experience using it; and e) the patient-physician 
relationship.   
2.5.1 The Transition into Menopause    
Participants reported distressing experiences of menopause that resulted in desperation 
and feelings of living in chaos. The distress they experienced during this transition was 
strongly linked to suffering abrupt, persistent, and severe emotional and physical 
symptoms.  Similar to other research findings, the majority of women in our study 
described hot flashes, night sweats and sleep disturbance to be the most frequently 
experienced symptoms and the most distressing. 29, 30  Vasomotor symptoms (including 
hot flashes and night sweats 2) are the most common menopausal symptoms to prompt 
women to seek care. 31, 32 The severity of vasomotor symptoms has been linked to lower 
levels of health status, reduced quality of life, and a decline in overall work productivity 
among menopausal women. 31, 33-36 Participants in our study spoke of similar difficulties 
in managing work and other daily responsibilities, and had contemplated significantly 
reducing their work load to accommodate their functional decline.  
Participants also described a sense of “loss of control” which enhanced their symptom 
severity and contributed significantly to their distress, which is similar to other studies.37-
39
  Feelings of confusion, isolation, and helplessness were pervasive among participants, 
and further impacted their social and occupational lives. Similar descriptions of 
alienation, trivialization of symptoms, lack of support and confusion have been reported 
in many qualitative studies, and have been linked to descriptions of distress. 40-42 Since a 
small proportion of symptomatic menopausal women seek health care, 1 and women who 
experience severe symptoms are the ones who tend to seek medical management,19, 43  
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family physicians need to realize the significance and impact of menopausal symptoms on 
women seeking care.  Proper attention and support by family physicians is critical in 
managing menopausal women’s needs and alleviating their distress. 
2.5.2 Quest for relief 
A sense of desperation was the primary factor that drove women in this study to a 
relentless search for symptom relief. The initial general search for “anything that works” 
was pervasive among participants. An online survey of 1663 women found that 80% of 
women wanted to try natural supplements before starting HRT;44in this study, and others, 
the reasons for trying a natural therapy included: feeling that it is more natural than HRT, 
and concerns about risks associated with HRT use.44, 45 Similarly, participants in our 
study experimented with multiple natural supplements but many also tried prescription 
medications.   Yet participants did not find much benefit from either the natural 
supplements or the prescription therapies which reinforced their desperation and 
propelled their search for a suitable solution until they found BHT.  
BHT was “discovered” by the majority of women in our study through “word-of-mouth”, 
mainly from friends and family members. Social support networks, including friends, 
partners and family members, are repeatedly cited in the literature as an important 
resource for women faced with menopause-related decisions in general. 46-49 Social 
exchange of information has also been specifically identified as a prominent supporting 
factor in women’s interest to use BHT.46  Reaching a state where they were willing to try 
BHT was a prominent turning point for menopausal women in this study. BHT signified a 
more hopeful outlook to menopause, as women were empowered to take control of their 
health care, and were determined to satisfy their intention to try BHT.    
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 Once women in our study discovered and intended to try BHT, they then focused their 
search on finding a suitable BHT provider that would help them access BHT. Our 
findings of this step wise approach to accessing BHT is supported by a qualitative study 
that explored women’s pathway to accessing BHT46 Women in that study reported 
barriers to accessing BHT that included; limited knowledgeable providers, physician 
reluctance to support BHT, and cost. 46 Participants in our study reported similar 
obstacles in accessing BHT, which resulted in significant frustration with the medical 
community.   
 Family physicians caring for women seeking BHT need to be aware of the dramatic shift 
that occurs in a woman’s overall menopause outlook when intending to try BHT. The 
intention to try BHT, based on this study, appeared to occur at the end of a struggle for 
symptom relief and was linked with a regained hopefulness in symptom resolution. Thus, 
attempts by physicians to explore the women’s reasoning for choosing BHT might be 
seen as attempts to deter its access. Family physicians need to approach this request with 
caution and with compassion to avoid any possible negative impact on the patient-
physician relationship.   
2.5.3 Decision to go on BHT  
The decision to go on BHT for the majority of participants in our study was a multi 
component process with four identified components: evaluation, resolve, reinforcement 
and conflict.  The process did not always occur in the order listed and participants 
repeatedly assessed and modified their commitment to each component. To our 
knowledge there are no other studies that explore women’s BHT decision making 
process. Studies have found that decisions regarding menopausal symptom management 
 48 
 
in general, as opposed to the use of BHT specifically have been found to be complex, 
highly individual, and to follow a non-linear iterative course that can be emotionally 
laden.8, 19, 49-52 Women’s decision-making process to use HRT has several stages that 
involve considerations of need, information seeking, weighing benefits and risks, 
applying beliefs and values, and interactions with social networks. 19, 49, 51-53  In our study, 
women approached their BHT decision-making process in a similar manner.  
Once being introduced to BHT, and contemplating the idea of trying it, participants 
proceeded through information-seeking to evaluate BHT as a therapeutic option. Studies 
have identified engagement in information seeking behaviour to be one of the initial 
stages women perform when making medical decisions.47, 52 The intention behind this 
initial step is to understand menopause and gather sufficient information on treatment 
options to make an informed choice.47, 51, 52 
In our study, the main information sources utilized by participants were media sources of 
information including magazines, books, television shows and the internet as well as 
social supports. Multiple studies have identified media and social sources of information 
to be more influential during women’s menopause management decision-making process 
than formal sources like physicians and other health care providers. 8, 19, 46, 49, 51This, in 
part, has been linked to an increased desire by menopausal women for guidance on the 
use of alternative therapies and hormone treatment that is not fully met by physicians’ 
preparedness to provide this information and guidance.45 In addition, many women have 
lost trust in medical recommendations since the publication of the WHI.50 However, 
information gathering and evaluation are not the primary deciding factor in women’s 
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intention to use hormone therapy; personal values and beliefs, along with past 
experiences, also shape women’s decision-making process. 47, 49, 54  
Participants in our study recognized multiple internal and external factors that influenced 
their choice and their resolve to use BHT including: beliefs that BHT was a more natural 
approach to menopause management, and being reassured by the lack of documented risk. 
Three studies that looked at women’s use of BHT support our findings of their beliefs that 
BHT is more natural and less harmful than HRT.18, 55, 56  However, a significant number 
of participants in our study did report concerns about BHT’s safety, primarily related to 
the safety of long-term use. Participants were conflicted by concerns regarding the long-
term safety of being on BHT and their fear of symptom recurrence if they discontinued 
BHT, especially after experiencing significant symptom reduction on this therapy. 
Although some women chose to periodically re-evaluate their need for BHT, the majority 
decided that their improved quality of life justified taking the risk. This can be explained 
to some degree by the subjectivity –relying on intuition and gut-level feelings– involved 
in menopause related decision-making.19, 51 In addition, experts are concerned about 
women’s possible misinformed understanding of BHT safety, and the role that this 
understanding plays in influencing their decision to use or stay on it.10-12, 57, 58  The 
influence of women’s perceptions of BHT safety on their decision-making process is an 
area that warrants further research. Such studies could aid family physicians in providing 
appropriate counselling to women on BHT that would also maintain a strong therapeutic 
patient-physician relationship.  
2.5.4 The Experience of Being on BHT 
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Women in our study reported immediate, significant and dramatic reduction in 
menopause symptoms after staring BHT. Many were astonished by their response, and 
were elated at their restored health and over all regained sense of wellbeing. Similar 
accounts of improved quality of life, restoration of emotional and physical balance, as 
well as renewed optimism and exuberance for life, have been reported in one previous 
study.56  There have also been some reports of significant symptom relief on BHT 
compared to HRT.55 Since there is paucity in studies that directly compare BHT to HRT, 
exploring the effect of BHT on women’s menopausal symptoms compared to HRT is an 
important area of investigation in future studies. Such research would provide a better 
understanding of BHT’s clinical benefit and role in menopause management, as well as 
influencing therapeutic guidelines. Inclusion of a placebo arm in such a trial might also 
provide valuable information on the contribution of expectancy and other psychological 
factors related to response to treatment.  
2.5.5 Menopause and the Patient-Physician Relationship   
Exploration of the participants’ reflections on the relationships with their family 
physicians throughout their menopausal journey revealed two distinct stages: a) stage one, 
family physician as life line; before participants discovered BHT and b) stage two, family 
physician as stepping stone; after participants discovered BHT.  
2.5.5.1 Stage One, Family Physician as Life Line 
Participants initially turned to their family physicians with hope for help and support 
during their menopausal transition.  Three important factors participants believed to be 
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missing during that initial stage: the physician’s realization of the significance of 
menopause, preparing women for menopause, and providing women with therapeutic 
options. These factors were considered pivotal in maintaining a satisfactory patient- 
physician relationship. 
2.5.5.1.1 Menopause is a Significant Time 
Participants in this study reported feeling their menopause concerns were trivialized by 
their family physicians. They felt unheard, and related it to: not being asked questions 
about their menopause experience, feeling their physicians offered prescriptions early and 
without spending sufficient time on counselling, and not exploring their individual issues. 
To our knowledge, only one previous qualitative study has explored women’s BHT 
experience and that study also reported that women were dissatisfied with their family 
physician interactions.56 Women in that study described a perceived disconnect in patient-
physician communication, a lack of compassion, and an overall disinterest in their 
needs.56 Although there is an increasing amount of knowledge on how women experience 
menopause 42, 59, 60 and multiple qualitative and quantitative studies on why women 
choose HRT or not, 8, 19, 49, 51, 54, 61-63 little is known about  menopausal women’s 
expectations during contact with their family physicians.  A few studies have identified  
some factors that contribute to women feeling supported during menopause related visits 
including: feeling the health care practitioner showed understanding, provided sufficient 
information to help them understand menopause, discussed treatment options, screened 
for other diseases, and put the women in charge of their decisions.8, 42, 64 However, those 
studies did not explore the factors that constitute a positive menopause related patient-
physician encounter. Thus, a clearer understanding of women’s experiences concerning 
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menopause health visits and their views on the role the family physician should take is 
necessary to enhancing patient- physician communication. Studies that focus on women’s 
thoughts and expectations during menopause counselling may significantly help family 
physicians better structure the time they spend and the materials they provide during 
menopause related visits.  
2.5.5.1.2  Prepare Women for Menopause 
Many participants in our study felt uninformed about what to expect during menopause, a 
factor that contributed to their sense of confusion and chaos. They talked about how 
physician-initiated menopause conversations and an anticipatory approach to menopause 
care through education and pre-emptive preparation could have significantly reduced their 
anxiety about experiencing new physical and emotional symptoms, as well as help 
overcome communication barriers. Studies have reported that women commonly express 
uncertainty in their expectations about menopause, 59, 65, 66 and lack knowledge about the 
spectrum of menopause changes.42, 59 Women’s confusion and lack of menopause 
knowledge has been partially attributed to the presence of social barriers that prevent 
women from discussing menopause and obtaining support from health professionals. 
These barriers include:  menopause being viewed as a taboo subject within society; the 
inability to seek support for fear of crying; and fears that discussion of menopausal 
symptoms might be viewed as attention-seeking.42  Even though a few participants in our 
study did talk about similar social barriers, the majority believed feelings of isolation, 
lack of sympathy, and embarrassment in communicating with male physicians were the 
main barriers interfering with their ability to seek support.  This variation in findings 
could partially be explained by differences in research methodology and participant 
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background between studies, as the previously mentioned study involved focus group 
interviews of participants that worked in a single health care facility in Scotland.  
It has been proposed that women have been taught from a young age that the physiology 
of their feminine bodies is private and should not be discussed. 66  Thus, a theme of lack 
of information extends throughout their lifespan and uninformed young girls develop into 
women whose knowledge, attitudes, and beliefs about menopause are shaped by 
insufficient information. 66 Educational programs on menopause have been shown to 
increase women’s knowledge about this transitional time and reduce their uncertainty. 67 
Women in our study also believed an anticipatory approach to menopause care through 
education could have significantly reduced their uncertainty and in turn anxiety about 
experiencing menopause symptoms.  Thus, early and pre-emptive discussions on 
menopause with women as they near that period in their life is an important opportunity 
for health promotion that would aid women in having realistic expectations of menopause 
and help them make healthy adjustments to experienced or anticipated changes.  
2.5.5.1.3 Provide Therapeutic Options 
Many participants were upset at the deficiency in therapeutic options offered by family 
physicians. They were also hoping that they would have a more active role in the 
therapeutic decision making process.  Repeatedly in the literature there is an emphasis on 
women’s desire to be actively involved in all aspects of their menopause care, especially 
in relation to therapeutic decisions.8, 48, 49, 68, 69  A review of 16 qualitative studies on 
women’s decision making about the use of hormonal and non-hormonal remedies for the 
menopausal transition, reported that women valued communication with their health care 
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providers as long as they were treated as partners in their care and were provided an 
environment that facilitated open dialogue and sharing of information.51 Women also 
wanted information about both HRT and alternatives, guidance about possible side 
effects, and assistance with weighing benefits and risks for both HRT and alternative 
therapies.48, 51,70  They appreciated providers who were available to answer questions, 
discuss concerns, and assist with problem solving and changes in regimens.48, 51, 70 
Participants in our study reported similar needs and considered them to be central to their 
satisfaction with their menopause related patient- physician encounter.  
Participants in our study and in other studies have expressed considerable dissatisfaction 
with the decision-making process involved in choosing menopause therapeutic options. 8, 
45, 71, 72
 Perhaps this may be explained in part because physicians may not be properly 
informed about the needs of patients and do not incorporate patients’ concerns and 
personal beliefs into the decision-making process. Women have identified multiple 
factors that are perceived to be relevant to their decision making about HRT including: 
spectrum of symptom response, preventative value, media reports and medical 
uncertainty.73  Yet  analysis of physician-directed clinical guidelines recommend that 
women be counselled on a fraction of those domains.73 Although lack of medical 
certainty regarding HRT has been acknowledged, there are no suggestions within clinical 
guidelines that guide a provider to address a patient’s feelings about making a choice in 
the setting of evolving evidence.73  Without shared recognition of the limitations of 
available data, true informed decision-making cannot take place. Thus the focus of 
menopause management dialogues should be on sharing information between physician 
and patient rather than simply giving information. Engaging menopausal women in such a 
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dialogue may lead to a better understanding of their illness experience, clearer perception 
of their therapeutic expectations, and ultimately reaching more informed decisions. This 
approach supports the need for family physicians to be patient-centered 74 during 
menopause counselling.  Recognizing and responding to each woman’s individual needs 
is crucial to the development and maintenance of a trusting patient-physician therapeutic 
relationship throughout women’s menopause journeys.   
 
2.5.5.2 Stage Two, Family Physician as a Stepping Stone 
In stage two, participants were focused on accessing BHT. The family physicians’ role 
was quite limited to either facilitating or impeding their ability to access this therapeutic 
choice. Factors valued by participants and considered key in facilitating their access to 
BHT were: family physicians expressed openness to BHT, their willingness to send a 
referral to a BHT provider and their support of the woman’s decision to use BHT. A non-
judgmental openness to this treatment modality was a vital quality in maintaining a 
satisfying patient-physician relationship. Participants were accepting of their physicians’ 
lack of BHT knowledge and did not consider it to be a major obstacle. Our findings are 
supported by a qualitative study that explored women’s path to accessing BHT.46 
However, women in that study differed from our participants in that they emphasized the 
importance of the providers BHT knowledge over other aspects, and considered the lack 
of BHT knowledge to be a significant barrier to their BHT care. 46 Women in our study 
did mention physician BHT knowledge as a possible barrier to BHT access, but more due 
to its effect on the physician’s comfort level with this modality and, therefore in turn their 
openness. This variation in findings could be related to the fact that participants in our 
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study were receiving their BHT care at a specialist clinic and did not rely heavily on their 
family physician's expertise.    
Many women were upset at their family physician's lack of follow up on their BHT 
experience, which they interpreted as a disinterest in their general menopause care. A few 
studies on women’s use of complementary and alternative medicine (CAM) during 
menopause recognize that physicians rarely ask patients about their CAM use and patients 
are reluctant to initiate that conversation.45, 48, 75  Physicians may avoid CAM discussions 
due to concerns about: lack of evidence, possible harmful effects, inadequate CAM 
knowledge and lack of statutory regulation for most CAM therapies.76  These findings 
suggest the importance of physicians’ openness towards BHT and willingness to be 
actively involved in their patients BHT care on patients’ menopause related health care 
and the patient-physician relationship. This is an important area for future BHT research 
to explore, as it would be valuable to have a better understanding of family physicians’ 
perspective on BHT, as well as patients’ expectations of the family physician’s role in 
their BHT care. This could help in the development of appropriate recommendations for 
approaching BHT conversations during hormone therapy counselling and shared decision 
making. 
2.6 Study Limitations  
The main limitation of this qualitative study is that the participant sample was composed 
of women on BHT who visited a single urban specialised BHT clinic.  This sample was 
purposefully chosen to insure all participants had experience of the phenomenon being 
studied, as we were interested in gaining a deeper understanding of how the decision to 
use BHT was made.  Given this limitation our findings do not reflect the experience or 
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decision-making processes of women who receive their BHT care through their family 
physician.  Consequently our findings may have captured a more negative view of the 
family physician-patient interaction during the BHT decision-making process than it 
would have if women who received their BHT care through their family physician were 
included.  Furthermore, the fact that all participants were actively receiving BHT at the 
time of the study may explain the overwhelming positive responses of participants to this 
therapy, probably reflecting a subgroup of women who BHT was helpful for. 
2.7 Conclusion 
This study has provided a more detailed understanding of menopausal women’s decision 
to use BHT as their therapeutic modality of choice. It has also identified that women who 
chose to use BHT experience a wide range of symptoms that significantly affect their 
quality of life. Family physicians should show awareness and understanding of the impact 
menopause may have on different aspects of women’s lives.  Anticipatory menopause 
counselling has been identified as an important source of reassurance for women and a 
key factor in developing and maintaining a satisfying patient-physician therapeutic 
relationship. It can begin as soon as women present with menopausal changes, or as they 
approach menopause. The content of the counselling should include expected changes 
and symptoms during menopause, what  life style modification women can do to manage 
these changes, a general discussion on risks and benefits of all available therapeutic 
options including; HRT, BHT and non-hormonal alternatives. Women’s options should 
be explained in a nonjudgmental way with BHT presented as part of a number of 
available choices and acknowledgment that there remains much uncertainty about the 
safety of many of the hormonal therapeutic options. The goal of the family physician is to 
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empower women through increased knowledge to reach an informed decision on their 
preferred management. The incorporation of different members of a health care team 
including nurses and pharmacists into the counselling process could aid this process and 
create a multidisciplinary and comprehensive team approach to menopause care. 
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Chapter 3  
Bio-Identical Hormone Therapy: A Qualitative Study of Family 
Physicians’ Experiences and Views 
 
The Women’s Health Initiative study (WHI) results published in 2002, indicated an 
increased risk for breast cancer, venous thromboembolism, cardiovascular disease and 
stroke from the use of combined estrogen/progestin hormone therapy. 1, 2 Since that time, 
there has been a significant decrease in overall hormone replacement therapy (HRT) 
prescriptions. It has been reported that HRT prescriptions decreased by around 38 percent 
in the first year after the WHI was published.3, 4 The findings of the WHI were widely 
publicized in the popular press, producing immediate and major impacts on women’s use 
of HRT. 3, 5 It has been estimated that up to 70% of women taking HRT stopped within 
the first year after the publication of the WHI results; 26% of these women also reported 
losing trust in medical recommendations in general.6, 7 More recent publications have 
criticized the widely publicized release of the WHI results, 8, 9 and questioned the 
interpretation and generalizability of its findings.10, 11 Even though multiple menopause 
societies, including The Society of Obstetricians and Gynaecologists of Canada (SOGC), 
have supported the use of HRT for symptomatic menopausal women, 12 much uncertainty 
remains among women and their health care providers about the safety of HRT.13, 14 
Due, in part, to the controversy surrounding the WHI, some women have chosen to use 
“bio-identical hormonal therapy (BHT)” or “natural hormones” as an alternative to 
conventional hormone preparations in the belief that they are safer.15-17 The "bio-
identical" approach generally refers to the individualized doses of hormones that are 
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delivered in pharmacy compounded creams, gels, pills, sublingual tablets, or 
suppositories. The hormones most commonly compounded are estradiol, estrone, estriol 
and progesterone.18-20 Studies about the use, safety, and efficacy of bio-identical 
hormones are limited because of small sample sizes and comparison of non-equivalent 
hormone doses. 15, 18-20   
A key area of concern is around women’s perception of BHT safety over HRT, and the 
influence that perception has on their decision making process.15-17, 21  Additionally, 
women have reported dissatisfaction with menopause related family physician visits and 
have described accounts of struggling with HRT treatment uncertainty.22-25 Family 
physicians have a fundamental role in supporting women during this transitional stage, 
and in providing them with sufficient information on available management options so 
that they may make an informed decision.13, 25-27  Yet studies have reported a significant 
change in family physicians’ menopause management practice patterns since the WHI, 
which involves a reduction in HRT recommendation, prescription and counselling.28, 29   
This has been linked to physician discomfort with HRT safety and adverse effects.29-31  It 
is therefore important to understand the possible influence family physicians’ perceptions 
of hormone therapy may have on women’s decision making process to use BHT. Since 
there were no studies found that examined family physicians’ perspectives regarding 
BHT or their experiences caring for women on this therapeutic modality, an appropriate 
initial step toward understanding family physicians’ roles in women’s BHT decision 
making process is to begin by exploring those domains.   
3.1 Purpose  
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This qualitative study set out to explore: 1) family physicians’ perceptions and thoughts 
about BHT, and their experiences with patients on this treatment modality; 2) the impact 
of the patients’ decision to use BHT on the patient-physician relationship. 
3.2 Methodology 
3.2.1 Study Design 
A phenomenological approach utilizing in-depth interviews was used. This approach 
carefully and thoroughly captures and describes how individuals make sense of a lived 
experience - how they perceive it, describe it, judge it, and feel about it - to better 
understand the nature or essence of the experience.32 An understanding of family 
physicians’ experiences with women using BHT is valuable for recognizing their role in 
caring for this group of patients, as well as to gain a deeper insight into the overall 
patient-physician relationship. 
3.2.2 Recruitment and Sampling      
Family physicians practicing in three counties in Southwest Ontario (i.e., Middlesex, 
Oxford, Elgin)  and who provided primary care to women 40 years of age or older were 
recruited for the study. Potential participants were identified  through the following 
methods: a) a random sample of 200 family physicians was drawn from a database of 
family physicians practicing in Southwest Ontario maintained by the Centre for Studies in 
Family Medicine at Western University; b)  participants of the “Bio-Identical Hormone 
Therapy: Understanding the Women’s Decision-Making Process” study (chapter 2) were 
asked to consider providing the name of their family physician; c) using snowball 
sampling, 33 family physicians who participated in this study were asked if they knew 
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other interested physicians; d)  the medical director at a clinic that provided BHT, and the 
research investigators’ medical colleagues were asked for recommendations of interested 
family physicians. Potential participants were mailed a letter describing the study and 
inviting them to join (Appendix IV).  Physicians who responded, met the study criteria, 
and consented (Appendix V) were interviewed.  Recruitment ended once theme saturation 
and maximum participant variation was achieved. 33  
3.2.3 Data Collection 
In-depth interviews were conducted between May to August 2012, using a semi-
structured interview guide (Appendix VI), at either the family physician’s office or 
Western University. The questions focused on the following areas: the physicians’ 
thoughts about BHT; their experience caring for women on BHT; their general role in 
managing menopause; and, the impact BHT use had on that role. Probes were used as 
necessary and the interview guide was adapted as new information emerged from the data 
analysis. Interviews, which lasted approximately 30 minutes, were audio-recorded and 
transcribed verbatim. Field notes and reflexive journaling 34-36 were recorded during and 
immediately following each interview. Participants received a $10 gift card in 
appreciation for participating. The study was approved by Western University’s Ethics 
Board (see Appendix VII)   
3.2.4 Data Analysis 
All interview transcripts and field notes were analyzed using an interpretive and iterative 
process that included: 1) initial familiarization with each participant’s whole descriptive 
account; 2)  organizing recurring words, phrases and significant statements from each 
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participant’s transcript into a coding template that was  grouped  in a similar fashion to 
the interview guide categories; 3)  generating themes, and using diagrams to compare 
themes among participants; 4) collapsing smaller subthemes within larger thematic units; 
5) identifying exemplar quotes that captured the themes; and, 6) producing the report.   
Data analysis occurred concurrently with data collection and continued until theme 
saturation was achieved (i.e., when no new themes emerged with further interviews).33  
Initially each of three researchers (LW, GR, AT∗) independently read each verbatim 
transcript. The researchers subsequently met to compare and combine their independent 
analysis on a regular basis, and synthesize the data in a comprehensive description of the 
key themes and overarching essence of the phenomenon. Techniques used to promote 
trustworthiness and credibility of the data included: a) purposeful screening to ensure 
exposure of participants to the phenomenon; b) audio-recording interviews, verbatim 
transcribing, detailed field notes to maintain methodological rigor; c) team analysis and 
reflexive journaling to maximize researcher transparency; and, d) constant referring back 
to data and field notes for verification of emerging themes. 
3.3 Final Sample and Demographics 
Participants (n=11) ranged in age from 35 to 64 years (mean= 48). Forty- five percent 
were women. All participants worked in London Ontario, with the majority (n=8) being 
                                                          
 
 
 
∗
 LW: Lemmese Alwatban , GR: Graham Reid, AT: Amanda Terry 
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employed in academic teaching clinics. The remainder (n=3) worked in urban non-
academic settings. All participants primarily practiced general family medicine and 
managed women in the menopausal age group (i.e., above age 40 years). The physicians’ 
years in practice ranged from 5 to 36 years (mean=18.45). 
3.4 Findings 
Four main themes emerged from the interviews: 1) physicians’ impression of BHT; 2) 
perceptions of patients’ knowledge; 3) the impact of BHT on the physician’s role; and, 4) 
reaching a therapeutic balance.  Participants expressed some concern about their patients’ 
understanding of BHT. Family physicians needed to reinforce risk assessment and to 
provide education regarding hormone therapy options so that their patients could make an 
informed decision when choosing BHT. They demonstrated awareness of the delicate 
nature of the menopausal transition for women and the role they played in managing their 
patients’ concerns, yet described challenges in reaching a balance between patients’ 
wishes and standard practice. The following describes each of the four themes in detail. 
3.4.1 Theme 1: Physicians’ Impression of BHT 
The majority of participants felt they had limited information about BHT.  The term “bio-
identical” was confusing to most physicians in the study.  They considered topical 
pharmaceutical HRT to be bio-identical in nature as it closely resembled the body’s 
natural circulating hormones.  BHT, defined in this study as a compounded form of bio-
identical hormones, was thought to be somewhat of a marketing strategy to differentiate it 
from the negatively publicized HRT.  Participants believed that BHT was not that 
different from HRT, as both were still hormones:  
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 I personally feel it’s a bit of a gimmick that someone’s come up with for financial 
reasons, to sell a product to a niche of patients exploiting their concerns.  That’s 
come a little bit out of some of the fear and anxiety around the women’s health 
initiative and traditional hormone therapy.  I don’t see it really is that much 
different than traditional hormone therapy.   
 
 Bio-identical hormone therapy is something that probably none of us feels like 
we know really a lot, and yet is that really true?  Because in terms of our hormone 
replacement therapy, we’ve learned with pills but then suddenly we’re using 
manufacturers topical [HRT preparations]. So how is that different than what this 
thing called bio-identical is?  I think that it may just be semantics.  There may not 
necessarily be that much of a difference. 
 
In spite of feeling hormones in BHT and HRT were not that different, family physicians 
consistently reported concerns about the lack of evidence supporting BHT: “from what I 
understand there have never been any controlled studies or any good studies to look at the 
validity of bio-identical hormones”. Many physicians also questioned the effectiveness 
and standardization of how BHT was prepared: 
You know when you’re compounding something you don’t really know what 
you’re going to end up with.  The amounts that would go into it might be different 
and then who knows what happens from there once it goes into your body.  There 
are so many variables that once it goes into the compound, you really don’t know 
how the body is going to treat it.  
 
In spite of concerns related to the preparation of BHT, physicians did not consider BHT 
to be more unsafe than traditional HRT and thus considered its clinical management 
comparable: “I don’t believe that they’re any more harmful than what we prescribe.  So if 
I had a comfort level in terms of a woman’s risk category to prescribe her hormone 
replacement therapy, then I would be comfortable supporting her in a trial of a bio- 
identical.”  
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3.4.2 Theme 2: Perceptions of Patients’ Knowledge 
All family physicians in this study expressed concerns with patients’ perceptions of 
BHT’s safety, and  felt patients were mislead by insinuations that it was more natural: “I 
must say a lot of them get taken in by the word ‘natural’ and that it’s similar to your own 
[hormones], and hence it’s not harmful. I think that’s the catch word that gets people to 
go and seek the bio-identical hormones”. Participants attributed the idea that BHT was 
safe to the information sources patients were referring to including word of mouth 
through friends and family members’ positive experience with BHT and promotion by the 
pharmacies prescribing it. The physicians particularly believed media sources like 
celebrity endorsement through television shows, books and magazines were especially 
influential in persuading women to choose BHT, as the following quote illustrates:   
I asked them [patients using BHT] about it: tell me why did you choose this 
versus the other? And again the same answer, they feel that it’s more natural and 
therefore it will not be as harmful.  Because everyone has heard about the WHI 
study, everyone knows what a bad thing HRT is and so this [BHT] to them is not 
synonymous with HRT. It’s a lesser evil or not even an evil  ...   Media [has had 
an effect] both ways in terms of saying bad things about HRT trials and promoting 
bio-identical hormones.… So fear generated by media and then a sense of security 
with bio-identical hormones generated by the media. 
 
Many physicians felt that the medical community might inadvertently be encouraging 
women to pursue alternative and non-HRT therapies for their menopausal concerns, 
because of a reluctance to prescribe HRT.  They believed that menopause for most 
women had a significant negative impact on their day-to-day lives which compelled them 
to search for a suitable treatment.  How physicians approached the topic of hormone 
therapy with their patients was also thought to contribute to the patients’ aversion to 
HRT, as reflected in comments like the following: 
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I think people feel uncomfortable with menopause. That’s perfectly fine, 
menopause is uncomfortable.  They [patients] now have had a huge [study] to tell 
you what doctors were doing was bad and therefore, they’re forced to say I need 
to do something and so they are actually pushed to bio-identical because we’re 
saying that hormones are bad. 
On the other hand, participants thought that the individualized delivery of BHT was 
perceived to be more appealing by patients than the traditional approaches in medicine.  
Many physicians felt that women who chose to try BHT were health conscious 
individuals who were invested in maintaining good lifestyle habits and were highly 
motivated to be involved in all aspects of their health care. These identified characteristics    
were believed to contribute to the patient’s satisfaction with the more personalised BHT 
approach, as exemplified in the following description:       
I think [BHT] meets a need for the patient in terms of ….a potentially much more 
personal approach, a more customized approach...  We like to customize things to 
have them the way we want.  I’m sure the patient feels much more involved in the 
whole process.  It’s probably more face-to-face time with the practitioner who’s 
helping them out.  So there’s probably a very positive perception from the 
patient’s point of view.   
 
General doubt in conventional medicine was another patient attribute that was considered 
by some family physicians to be a reason for using BHT: “[patients] who probably stay 
with the bio-identical come hell or high water tend to be, generally speaking, a particular 
group of people who do not trust medical things per se but have found their symptoms so 
dramatic. A lot of their life is focused on sort of natural approaches and that type of thing 
and taking control of themselves.” 
3.4.3 Theme 3: The Impact of BHT on Physicians’ Roles 
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Family physicians recognized their important role in caring for women during the 
menopausal transition, but they expressed differing opinions about how to address 
women’s concerns. Female physicians in this study felt strongly about preparing women 
for menopause and taking an anticipatory approach to their care by dedicating sufficient 
time, educating them on symptom variations, available treatment options, and possible 
effects on their overall wellbeing.    
Unique to menopause is a tremendous amount of information giving; perhaps 
more complicated than say a birth control visit.  Managing expectations, 
confirming the normality of it all, giving some idea of sort of the options in 
general -medication, non-medication- other life issues that are going to occur at 
the same time; It’s part of a process it’s a stage [and] a very complicated time in 
their life! 
 
Conversely, male physicians viewed menopause to be no different than any other medical 
condition: 
I think it’s just one of the things we do with managing any other medical 
problems. [Menopause is] a medical problem, so it’s a must that we [manage] this. 
I would discuss what menopausal symptoms are and what is going to be as they 
go through this change in life … We do this sometimes in periodic health exams.  
 
 Both male and female physicians described a definite stepwise approach to menopausal 
care that involved identifying symptoms and their impact on women’s lives, using 
medications when appropriate, risk assessment and ongoing monitoring, and reaching a 
joint decision on when to discontinue the medication.  The majority of physicians felt that 
being on BHT impeded the women’s usual flow of care:  
 Normally, we try to keep in contact with our patients and follow-up.  Even when 
a specialist prescribes a new medication often it would come back to us to 
continue to follow the medication and continue to prescribe it.  So [BHT] is really 
a different model, where they’re getting something from somewhere else and not 
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really necessarily following up with us about it ... I think it’s changed that ongoing 
follow up piece, It tends to fall off the radar a little bit because it’s maybe not on 
their medication list, or that they feel they’re dealing with somebody else, so they 
don’t always bring it up. 
 
Many physicians were disappointed at not having a direct role in this aspect of their 
patient’s care “I wasn’t in the driver’s seat. I was in the back seat!”  “I think on some 
level I feel that as her doctor I’m a little bit left out in the process”. They described 
feeling that their patients did not trust them when it came to talking about hormone 
therapy and believed that perhaps the BHT information sources were contributing to this 
impression.   
... There’s a bit of disbelief by the patient in terms of well “he [the family 
physician] doesn’t really know what he’s talking about”.  I sometimes get that 
inkling; like they don’t trust you because you’ve been set up to be on the bad side. 
 
The timing of when physicians talked to patients about hormone therapy was considered 
crucial in influencing the patients’ thoughts about BHT, “It depends who gets to them 
first”. One family physician described her frustration at missing that opportunity as 
follows: 
There were a couple of [women] that really did think [BHT] was great and that it 
really did work for them. From that standpoint it was a little bit more awkward, 
because they had already experienced it and really thought that it was the better 
way to go, without really knowing what the alternative was.  So it was a bit one 
sided!   
 
3.4.4 Theme 4: Reaching a Therapeutic Balance 
Physicians struggled to achieve a balance between patients’ wishes and standard practice:  
“... how do you balance all of that?  Sort of the feeling uncomfortable, not knowing this 
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type of modality [BHT] and patients wanting it and needing it or thinking they need it”.  
Physicians identified some factors that contributed to their discomfort in providing BHT 
care including: lack of knowledge, concern about safety, and the potential for medico-
legal consequences. 
3.4.4.1 Lack of Knowledge Regarding BHT 
All family physicians interviewed felt the lack of BHT knowledge put them at a 
disadvantage in providing patient care, as demonstrated by the following participant’s 
response: 
Lack of knowledge! Don’t you love it when the patient comes in and wants to talk 
about something and you can tell you’re at the deep end and you have no idea 
what you’re doing there. 
 
 Family physicians reported briefly looking up literature on BHT only when patients 
requested this treatment. Many physicians did not feel the need to invest more time in 
learning about this modality as they did not have a sufficient number of patients interested 
in it. Two female physicians who had a higher proportion of female patients in their 
practice felt justified in enhancing their understanding of BHT.  Participants who worked 
in academic-teaching practices did not feel the need to purposely teach BHT to family 
medicine residents, but rather focused on hormone therapy education in general. They 
only felt the need to talk about BHT when residents interacted with patients requesting it, 
and would mostly approach the conversation as they would other ambiguous areas of 
primary care practice:  
Well I think it’s the role in teaching people about any uncertainty, and I kind of 
explain how I talk to patients about it, and that’s what I talk to residents about, 
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because I’m not going to be able to teach them everything. I’m not going to tell 
them which bio-identicals are good or bad. 
 
3.4.4.2 Concern about Safety  
Most participants approached their concern about BHT safety by initially offering 
patients alternative and more familiar therapies, including HRT.  Once patients rejected 
those options, most physicians felt they had an important role to play in providing their 
patients information on BHT’s probable risk, and to compare those risks to conventional 
HRT. The goal of these conversations was not necessarily to change patients’ decisions, 
but rather to insure that they were making an informed decision.  
You just have to accept that often, especially around this particular issue where 
there are very strong opinions ...  it’s not really worth fighting their opinion. It’s 
just providing information, helping to make sure that they can make the best 
decision for them, and leaving it at that, and trying not to make it a fight. 
 
Family physician’s BHT-care centered on risk reduction by screening patients for 
hormone risk factors as well as encouraging their maintenance of routine monitoring.   
The issue of safety was of particular concern when patients were considered to have too 
high a risk for conventional HRT:  
I think there was a misconception that BHTs were somehow not harmful. I 
thought that was a big problem, because there were people on them that I didn’t 
think should be on hormone therapy at all! Because of a family history of breast 
cancer or something like that. But somehow they were given the impression that 
the bio-identical hormones were better for them, so I thought that was an issue! 
 
Unless I have an obvious alarm that goes off - personal history of breast cancer, 
something that says, “No, you shouldn’t be doing this.” - You let people make 
those decisions. 
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3.4.4.3 Potential “Medico-Legal Consequences” 
Participants were hesitant in prescribing BHT to patients as it was not part of standard 
practice, yet they were willing to support their patients’ BHT choice only if they felt they 
were also suitable candidates for HRT, as exemplified by the following physician’s 
response to being asked about his comfort with BHT. 
I think from a medical legal perspective, if I’m thinking with that hat on, the 
answer’s no. It’s not a form of therapy that I’m familiar with.  From a patient care 
perspective, I have less of an issue because in this case I’m playing more of a 
supportive role, a facilitator role. 
 
 Many physicians explained how their patients specifically requested BHT, and brought 
in information pamphlets or even prewritten examples of prescriptions. Although 
physicians described feeling “uncomfortable” writing out the BHT prescriptions, they 
agreed to it if the hormones requested and their dosages appeared reasonable and 
comparable to conventional HRT. Many of the physicians interviewed reported 
documenting the patient’s understanding of this treatment’s “off-label use” and the 
patient’s awareness of the possible risks associated with hormone use.  Physicians were 
reassured if BHT was initiated by a medical specialist as they believed patients would be 
properly monitored:  
A few patients that have been on them [BHT] were followed very closely and 
were prescribed these hormones by a gynaecologist, so I felt fine, comfortable 
with it. Whether I would choose to prescribe them, probably not! I think knowing 
that the person who is prescribing them was well educated and well versed in bio-
identical hormones and other hormones as well.  He or she knew what they were 
doing, so there was that safety zone. 
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Even though family physicians in this study prescribed BHT at a patient’s request or as 
refills, the majority were not open to initiating this therapy or offering it as a therapeutic 
option. 
I’d have to have a woman asking for [BHT] and remind me what we’re treating.  
We’ve got to be treating something here, and have an end point.   I’d likely want 
to talk about how long because I wouldn’t think forever is the right answer.  
Instead of me convincing them, they have got to convince me.   
 
Overall participants described that the process reaching “common ground” with patients 
was essential to maintaining the patient-physician relationship. Being open to 
unconventional care and willing to listen to patients were considered to be key factors in 
attaining a collaborative relationship, 
 
I think overall you have to make sure that it’s an open practice to be able to 
discuss [BHT]. If you have a very paternalistic approach … then you’re not going 
to get the person to talk to you. 
 
Just being open to listen and actually really make clear your position about [BHT], 
because patients do often come in with their guards up about how much to inform 
the physician ... I think the approach we’ve taken is good - listening and 
partnering with them to achieve the goal, which is their health.      
 
3.5 Discussion  
 
Family physicians in this study identified several challenges in providing menopausal 
care to patients on BHT, four major themes emerged: 1) the physician’s perspective on 
BHT; 2) perceptions of patient’s knowledge and understanding of BHT; 3) the impact of 
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this treatment on the physician’s role; and 4) reaching a therapeutic balance. To our 
knowledge, there are no previous studies examining family physicians’ perceptions and 
thoughts about BHT, their experiences caring for patients on this treatment modality, or 
the impact patients’ use of BHT may have on the patient-physician relationship. 
3.5.1 Physician Perspective on BHT 
Physicians in this study reported a lack of knowledge about BHT, but felt that the 
hormone constituents were no different in effect and risk from conventional HRT – 
“hormones are hormones”.   Although there are no studies specifically examining 
physicians’ views on BHT there are multiple papers suggesting a consensus among 
experts about its comparable risk to HRT.19, 21 These papers support our participants’ 
views that BHT should not be considered risk-free but rather, considered as an alternative 
hormone treatment. The International Menopause Society (IMS) and The North American 
Menopause Society (NAMS) have issued statements supporting this position: “In the 
absence of efficacy and safety data for BHT, the generalized benefit-risk ratio data of 
commercially available HT [hormone therapy] products should apply equally to BHT”.37, 
38
  
Physicians in this study also expressed confusion around the term “bio-identical”. They 
considered both the lack of BHT knowledge and the confusion around terminology to be 
sources of discomfort when they counselled patients on BHT use. Comparison studies 
about physicians’ knowledge regarding other forms of complementary and alternative 
medicine (CAM) have repeatedly reported similar discomfort with CAM knowledge 39-42; 
this has been linked to a low rate of discussion about CAM issues with patients.42 
Furthermore, conversations around BHT may have the added complexity associated with 
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talking about hormone therapy in menopause.  Studies have identified general discomfort 
among physicians in counselling women on HRT.30, 31 Uncertainties around hormone 
therapy safety and the lack of decision aids have been cited as possible causes for 
physician discomfort. 30   
Other studies have noted physician interest in learning more about CAM therapies.39, 40, 42  
In contrast, physicians in our study did not believe there was a pressing need to expand 
their BHT knowledge as they did not feel its use was prevalent enough. Data on the 
extent of BHT use in the population are scarce; one study estimates the prevalence of 
compounded BHT use to be about 20% among menopausal women seeking care. 16 
However, the prevalence of CAM use among menopausal and peri-menopausal women 
ranges from 50%-75% in North America and the UK,43-46 and one estimate suggests 95% 
of women would try alternative therapies before considering HRT. 47 Since most studies 
did not specifically exclude BHT from their reports on CAM prevalence, the extent of 
BHT use may be higher than predicted. There is a need to obtain better estimates of the 
use of BHT in the population.  It is of value for primary care physicians and policy 
makers to have a better understanding of the degree of BHT use and interest among 
women, to help with allocating time, effort and resources to this area of menopause care. 
3.5.2 Perceptions of Patient’s Knowledge 
In the literature - including review articles, physicians’ opinions and research studies on 
patient knowledge - there appears to be much concern about patients’ understanding of 
BHT safety, and its possible influence on their preference to use it. 15, 17-19, 21, 48, 49 One 
study specifically assessed patients’ perceptions of BHT, 17 and multiple review articles 
have analyzed different BHT internet sources, pharmacy advertisements and celebrity 
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endorsements, and have identified the use of persuasive and misleading terminology in 
the description of this treatment such as: “natural”, “risk free” and “preventative”. 15, 17-21 
Participants in our study had similar concerns, but also felt that the dissemination of the 
WHI study’s negative outcomes and patients’ fears of conventional therapy were 
instrumental in their selection of BHT. Similar results were found in a qualitative study 
conducted with family physicians, internists and gynaecologists in the USA. 30 Physicians 
interviewed in our study felt that the medical community may also be contributing to 
patients’ aversion to HRT, by emphasising HRT risk discussion during menopausal 
counselling. Physician discomfort with HRT due to safety uncertainty has been well 
documented. 30, 31 But it remains unclear if physicians’ discomfort with HRT can 
influence patients’ choices. One study of women facing breast cancer 
prevention/treatment decisions found physicians’ anxiety from medical uncertainty was 
significantly associated with women’s level of satisfaction with breast health decisions.50  
If physicians’ attitudes towards medical uncertainty may influence patients’ decision 
outcomes, it could impact the shared decision making process. Although there is growing 
literature on medical uncertainty with regard to patients’ illness experiences, prognosis 
and communicating risks, little attention has been given to communicating uncertainty.51-
55
 Even though general recommendations have been made by different panels of experts,  
data is lacking regarding outcomes of these approaches for either physicians or patients 
involved in the decision making process.55 Thus future studies especially examining the 
relationship between patient behaviours that may be affected by physicians’ attitudes 
towards uncertainty are warranted. Such studies could aid in the development of 
appropriate recommendations for addressing uncertainty during hormone therapy 
counselling. 
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3.5.3 BHT Impact on the Physician’s Role 
Although menopause is a natural process, women have described accounts of suffering 
prolonged symptoms and struggling with HRT treatment uncertainty.22-24 Family 
physicians have a fundamental role in supporting women during this transitional stage.  
Detailed and informative menopausal counselling for women, both to help them 
understand symptoms and to explain available management, is required.13, 25-27  Family 
physicians in our study described different approaches in addressing menopause 
counselling based on their gender. Female physicians felt that counselling women on 
menopause involved discussions on multiple aspects of care which justified allocating 
specific and sufficient time to their conversation. On the other hand, male physicians 
were comfortable incorporating menopausal counselling into a longer periodic health 
visit. There may be a preference among women for dedicated menopause visits with 
ample time for discussion and enquiry.13, 25 Furthermore, the complexity involved in 
reaching a decision on management may require a prolonged medical encounter.26, 27, 56  
Time constraints during routine clinic visits have been cited as a barrier to optimal 
communication regarding menopause.25  Thus, allocating longer visits for the discussion 
of menopause may be beneficial. With the movement toward team-based care in Canada, 
the involvement of nurse practitioners or clinical pharmacists in counselling patients on 
menopause is another option to consider.       
Participants in this study expressed concern and disappointment at the impact BHT use 
had on patient care and believed early discussions with patients about menopause may 
help maintain a therapeutic relationship.  Similar findings have been reported by 
physicians caring for cancer patients receiving CAM.57, 58 Physician initiation of CAM-
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related discussions with patients has been thought to promote strong, trusting and healing 
patient-physician relationships.57-59 Incorporating discussions on BHT early within 
routine menopause counselling may help bridge the communication gap and maintain a 
strong therapeutic relationship, as well as encourage patients to approach BHT 
information sources with a more analytical view.  
3.5.4 Reaching a Therapeutic Balance 
Reaching a balance between patient’s wishes and standard practice was identified as a 
challenge in caring for patients using BHT.  Physicians associated this challenge with 
their lack of BHT knowledge and especially their concerns about its safety and possible 
medico-legal implications. Physicians focused their efforts on emphasising the 
importance of risk assessment and patient education, to ensure their patient’s decision to 
use BHT was well informed. Participants felt the timing of such conversation was 
imperative in influencing patients’ perceptions about hormone therapy and in maintaining 
a therapeutic relationship after initiating BHT. The delay in initiating BHT conversations 
until patients request this therapy may result in potential missed opportunities for 
physicians to influence their patients’ comprehension of inherent risks and may 
negatively impact the shared decision making process once patients have reached a 
resolve about using BHT. A qualitative study of menopausal women’s information 
sources has indicated that most women still rely heavily on their physicians as a first 
professional source of health advice and information.60 Although other studies have 
suggested the utilization of information sources like media and personal contacts, they 
described those sources as being less influential than physician input.61, 62 However, 
studies on women’s decision-making during menopause have identified that  less than 
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optimal menopause counselling may result in women’s dissatisfaction with the medical 
encounter and in turn the loss of a trusting relationship.13, 25, 63, 64  
What is clear from the literature is that the current approaches in menopause care are 
inadequate in producing a fully informed patient who is able to reach a satisfying 
therapeutic decision.13, 25, 63, 64  For that reason particular attention needs to be paid to 
proper menopause counselling, that incorporates discussion on different avenues of 
management in a nonjudgmental compassionate manner. This approach supports the 
family physician’s need to be patient-centered 65 during menopause counselling. 
Understanding menopausal women’s illness experience and responding to their individual 
management needs is crucial in empowering women to reach an informed therapeutic 
decision while maintaining a strong trusting patient-physician relationship.  
 
3.6 Study Limitations  
The main limitation of this study was that the participant sample was from urban or 
academic settings in one city located in Southwest Ontario. As such, views obtained may 
differ from family physicians working in non-academic settings or in smaller rural 
communities that might not have the same level of exposure to BHT.  However, the 
physicians in this study were purposely chosen to ensure all participants had experience 
caring for patients on BHT.  
 
3.7 Conclusion 
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Communicating about menopause raises difficult issues for both patients and physicians 
around symptom diversity, therapeutic uncertainty and fear of treatment risks, hence the 
importance of proper counselling. It is imperative for physicians to appreciate the 
complex nature of the therapeutic decision making process and approach it with 
compassion and understanding.  Additionally, the role of the physician is not to decide for 
a patient whether to accept or decline the various forms of hormone therapy but to 
provide sufficient information so they may make an informed decision. Involving 
different members of a health care team as well as communicating with the patient’s BHT 
practitioner may significantly enhance the counselling process, resulting in a better 
comprehensive team approach to menopause care. 
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Chapter 4  
General Discussion and Integration of Findings 
 
Despite considerable controversy concerning the safety and efficacy of BHT, 1-4  and the 
lack of endorsement by the majority of menopause societies, 5, 6   there are some women 
who have chosen to use BHT to manage menopause.  A prominent concern about  BHT 
use is around the possible influence misleading terms like “bio-identical” and “natural” 
may have on women’s perceptions of  BHT safety and in turn, their decision to use 
them.4, 7-9  Descriptions of women’s use and path to accessing BHT exist in the 
literature.10, 11 However, to date there have been no studies directly exploring  women’s 
decision-making process in choosing this therapeutic modality, or the possible influence 
family physicians may have on this process. This thesis sought to explore this 
phenomenon from the perspectives of both women who use BHT and the family 
physicians who care for them.   
To capture the phenomenon under study, two complementary and sequential qualitative 
studies were conducted.  The studies involved in-depth interviews with women using 
BHT and family physicians that care for this population.  Below, findings from each 
study are compared and contrasted and over- arching themes are highlighted. General 
recommendations and possible policy implications related to the decision-making process 
of using BHT are then presented. 
4.1  Integrated Summary of Findings  
There was strong congruence between the findings from the interviews with women and 
family physicians. Common themes include: 1) the complexity of menopause counselling, 
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2) the dichotomy between women’s and physicians’ views of BHT, and 3) the patient- 
physician relationship.   
4.1.1 Theme 1: The Complexity of Menopause Counselling 
There was synergy in participants’ accounts of the impact menopause had on women’s 
quality of life. Participants in both studies recognized the significance of this transitional 
period and the importance of the family physician’s role in reassuring and normalizing 
women’s menopause experiences.  Furthermore, participants unanimously expressed how 
they believed a pre-emptive approach to menopause counselling was vital in relieving 
women’s fears and confusion about menopause symptoms.   Women participants 
emphasized the importance of having sufficient time during menopause-related visits with 
their family physician to fully explore their concerns and discuss therapeutic options. 
However, only female physicians felt menopause counselling was complex and required 
longer and dedicated health visits to ensure women felt supported; male physicians did 
not express these ideas.  This in part could be explained by female physicians general 
tendency to provide more female preventative care,12, 13 spend more time with patients, 
engage patients in discussions of  social and psychological contexts  and facilitate  patient 
participation and partnership more effectively  than  male physicians.12, 14-16  The gender 
difference in approaching menopause counselling could result in women feeling a lack of 
empathy from male physicians.  Many women participants in our study did talk about the 
physician’s gender as a possible obstacle in their menopause health care, yet most women 
participants felt it was something that could easily be overcome. Women suggested that 
male physicians should initiate the conversation on menopause; show knowledge related 
to women’s health; spend sufficient time during visits; and demonstrate a caring attitude. 
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Studies have identified that patient-centeredness; sufficient visit duration; and the 
demonstration of compassion can eliminate patient perceived gender bias.15, 17-19 Also, 
there appears to be a preference among women for dedicated menopause visits with 
ample time for discussion and enquiry.20, 21 Furthermore, the complexity involved in 
reaching a decision on menopause management may require a prolonged medical 
encounter.22-24 Both of our studies support the value of dedicated menopause visits that 
provide patients with adequate time to explore their concerns and discuss management 
options.  This is a critical finding, since primary care clinic time constraints may be a 
factor interfering with the physician’s ability to provide satisfactory counselling 
durations. This could result in women’s dissatisfaction and loss of trust in conventional 
medical care. 20, 21, 25, 26  A few studies have identified nurse practitioners and pharmacists 
to be important resources for women going through menopause.21, 27 Thus, the 
incorporation of a team approach in menopause care that would involve both nurse 
practitioners and clinical pharmacists could aid in providing patients with the necessary 
counselling duration, as well as providing support in reaching a decision on menopause 
management.  Other approaches to consider would be the use of educational material like 
pamphlets, websites or public lectures that would serve as an initial foundation for more 
focused menopause counselling during clinic visits. The latter approach also provides 
women with additional knowledge, which has been shown to reduce uncertainty and 
anxiety during menopause. 28 
4.1.2 Theme 2: The Dichotomy between Women’s and Physicians’ Views of BHT 
Participants from both studies strongly endorsed the concept that women’s resolution to 
use BHT was a critical junction in their menopause care. It was identified as a turning 
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point in women’s views of their family physician’s role during menopause.  The family 
physician’s scope of menopause care was significantly reduced to either providing a BHT 
prescription, or a referral to a BHT provider. Family physician participants also reported 
that menopause counselling was no longer effective after women had reached a resolution 
to use BHT.  Data from both studies identified women’s fear of HRT and belief that BHT 
was a safer alternative to be a strong factor in influencing their decision to use BHT. This 
was further supported by the women’s significant symptom resolution on BHT.  The 
dichotomy arose between women’s beliefs of BHT safety and family physicians’ 
concerns about the unsupported nature of those beliefs. This dichotomy is also evident in 
the literature as studies of women using BHT have identified similar beliefs that BHT is 
less harmful than HRT, 7, 8, 10 while physicians have voiced concerns about those beliefs, 
1, 3, 4, 8, 9, 29, 30
 and the majority of menopause societies have not endorsed BHT use 5, 6     
Physicians’ reluctance to support this treatment modality was considered by women 
participants in our study to be a barrier to BHT access, and in turn the physicians’ 
perceived closed attitude was a source of dissatisfaction with care. Similarly studies on 
other forms of alternative medicine have identified the openness of the health care 
provider to the patients chosen modality of care to be a key factor in promoting 
collaborative care.31-33  Although both women and physician participants in our studies 
did recognize that the physician’s openness to BHT was imperative to maintaining a 
therapeutic relationship thereafter, it is unclear what constitutes an open attitude, or what 
factors are fundamental in conveying openness to BHT.  Future research which would 
explicitly explore women’s expectations during BHT requests or even other forms of 
alternative therapy requests would be valuable in helping to bridge communication 
barriers and lessen misinterpretations.  
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4.1.3 Theme 3: The Patient-Physician Relationship   
Patient-physician communication is perhaps the most significant component of the 
medical encounter, is a bridge to finding common ground, and the cornerstone of a solid 
therapeutic relationship.33-35  Participants from both studies identified “listening” to be the 
most impotent factor in establishing a satisfying menopause related patient-physician 
encounter.  
As a [family physician] community we could improve the [menopause 
counselling]  process by being more upfront about our willingness to listen ... 
because we don’t make that explicit, and I think a lot of patients have the 
perception that it’s them versus us. 
Women participants especially reported feeling heard by their family physicians if they 
demonstrated interest in their menopause experience and the impact it had on their quality 
of life.  Unfortunately, many women were unsatisfied with their initial menopause related 
health visit as they felt rushed into taking a prescription to manage their symptoms, which 
suggested a lack of the family physicians’ interest in their menopausal experiences.   
Although family physician participants in our study reported approaching menopause care 
in a step- wise manner that involved symptom exploration, menopause education, 
reassurance, and management counselling, women participants did not perceive that 
approach.  This variation in findings could be related to the fact that none of the physician 
participants in our study were involved in the actual care of the women participants. As a 
result, participant specific patient-physician dynamics would not be captured.  However, 
studies that have reported on women’s positive menopause-related physician encounters 
identified a similar approach to menopause care.36  These findings signify the importance 
of the physician adequately exploring women’s menopause experiences and the effect it 
may have on women’s satisfaction with the overall patient-physician encounter.     
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A prominent finding between the two studies was the exclusion of the family physician 
from women’s menopause care as a consequence of BHT use.  Participants from both 
studies demonstrated disappointment at this loss and sought a more shared approach to 
care.  Women participants interpreted family physicians lack of interest in their BHT use 
as disinterest in their overall menopause care. Similar communication gaps have been 
identified between physicians and cancer patients who use complementary and alternative 
medicine (CAM).31, 37 However, the patient-physician relationship was enhanced when 
the topic of CAM was discussed.38  Physician initiation of CAM-related discussions has 
also been thought to promote strong, trusting and healing patient-physician 
relationships.31-33  Thus, the importance of family physicians’ listening skills and their 
expressed interest in women’s menopause experiences appears to be particularly 
important in the context of BHT.  This aspect of women’s care would significantly 
benefit from family physician initiated conversations and continued follow up to ensure 
the preservation of the patient-physician relationship.   
4.2 Thesis Limitations  
The findings of this thesis are not intended to be generalized to all family physicians, nor 
to all women seeking menopause care. Although physician participants possessed 
common practice profiles in urban or academic locations, they did reflect diversity with 
respect to their gender, age and years in practice. Despite this limitation, all physician 
participants in our study did care for women on BHT in their practice and thus their views 
do reflect family physicians actual experiences with BHT care regardless of their practice 
location.   
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Patient participants reflected a balance in age, menopausal status, years since last period, 
prior HRT and duration of BHT use; they were all recruited from an urban, specialized 
BHT practice.  Since participants received their BHT care at a specialist clinic and did not 
rely on their family physicians for that aspect of their care, this may have contributed to 
the exclusion of their family physicians from their overall menopause care. In addition, 
the perspectives of patients who might be receiving BHT through their own family 
physician could not be captured.  However, a more in-depth understanding of family 
physicians’ and women’s experiences with BHT, specifically what influences the 
decision-making process was achieved.  
4.3 Conclusion  
The collective findings of both studies demonstrate the complexity of menopause care.  
The findings offer important information about the role of the family physician and the 
patient-physician relationship in the journey of women choosing to use BHT to manage 
menopause symptoms; in particular the value placed on family physicians spending 
adequate time exploring women’s experiences, listening to their concerns and being open 
to the independence of their therapeutic choices. This thesis also demonstrates that 
women seeking menopause care regard the primary care practice as a place of support, 
reassurance and education, and are hoping for a more shared approach in their menopause 
care; especially with regard to the implementation or organization of varying treatment 
options. 
The integration of a team approach in menopause care is a strategy that could support the 
process of comprehensive menopause management. Since counselling is particularly 
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important, different team members could be more closely integrated into patient support 
and education.  The value of a team based approach resides in its ability to achieve and 
maintain satisfactory menopause care within the primary care setting and in reducing 
health care fragmentation. 39  In order to make this a reality; action on the part of policy 
makers and medical organizations is required to increase facilities and funding available 
for collaborative team based menopause care. 
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(Appendix I ) Letter of Invitation for  Women’s Study 
Southern Ontario Fertility 
Technologies (S.O.F.T.) 
xxxxxxxxxxxxxxxx 
Tel: xxx-xxx-xxxx 
  
 
Date:  April 9,
 
2012 
Dear <<Patient’s Name>>, 
Researchers from Western University are doing a study exploring menopausal women’s 
thoughts and experiences receiving Bio-identical hormone therapy (BHT). This is being 
studied so that family physicians might have a better understanding of menopausal women’s 
choice to use BHT and in turn will be able to provide them better care.  
You are being invited to participate in an interview as part of the study, entitled ‘Bio-
Identical Hormone Therapy: Women’s Decision-Making Process and Family Physicians’ 
Views’ as you have been identified through our records to be a women experiencing 
menopause who has received Bio-identical Hormone Therapy (BHT). The interview will take 
approximately 45-60 minutes, and take place at a location and time that is convenient for 
you. If you prefer, a telephone interview could be arranged.  You will be asked to respond to 
a series of questions about: your menopausal experience, your thoughts on BHT and 
experience using it. The researchers are looking for women of the age of 40 or older who are 
on BHT.  
Your decision to participate or not will not affect the services you receive at the Southern 
Ontario Fertility Technologies (S.O.F.T.) 
If you are interested in participating or have questions about the study please contact Dr. 
Lemmese Al-watban at (xxx) xxx-xxxx or email her at xxxxxxxx@xxxxxx  or Dr. Graham Reid at 
(xxx) xxx-xxx x. 
Thank you for considering participating in this study  
 
<<Signature of SOFT clinic professional>> 
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(Appendix II ) Interview Guideline for Women’s Study 
INTERVIEW GUIDELINE: WOMEN PARTICIPANTS 
 
Introduction to interview: 
This study is about exploring menopausal women’s thoughts and experiences about 
receiving Bio-identical hormone therapy (BHT).  In this interview, I will be asking you 
questions in five main areas relating to your menopausal history, your menopause 
treatment history, your decision to use BHT, your experience using it and your family 
doctor’s role in managing your symptoms. At the end of the interview I will ask a few 
demographic questions. The aim of the interview is to better understand your experience 
as a women going through menopause and your choice to use BHT. 
 
A) Menopausal history and symptom severity:  
To begin, I would like you to tell me about what the transition to menopause was like for 
you. 
Probe for the following if they do not emerge: 
- In what ways has menopause affected you physically? 
- In what ways has menopause affected you emotionally? 
 - In what way did menopause impact your life? (Work, social or interpersonal 
relationships)  
 
B) Treatment history before bio-identical hormones: 
 Now, that you have told me about your experience of menopause. I am interested in 
what you did to help relieve the symptoms of menopause before you tried Bio-identical 
hormones (BHT)? 
Probe for the following if they do not emerge:  
- Tell me about your experience with any medications or herbal supplements that you 
took before BHT to help with your symptoms?   
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C) Decision to use BHT:  
1) Since you have shared with me your experience with other menopausal treatments, I 
would like you to tell me about what made you decide to use BHT? 
Probe for the following if they do not emerge: 
-Did anyone influence your decision (friends, family, members of health care and 
alternative practitioners)? How? 
-What attracted you to this treatment or what made it appealing?  
- What were some of the concerns you had about BHT? How did that influence your 
decision to use it? Do you still have those concerns? 
2)  Where did you learn or hear about BHT? (Information sources)  
Probe for the following if they do not emerge: 
-Do you feel you have a good understanding of this treatment (effects and risks) 
- In your opinion how is BHT different from conventional HT that your family doctor or 
gynecologist might prescribe?  
 
D) Personal experience on BHT: 
Now that you have shared your reasons for choosing BHT, could you tell me about your 
experience using it? 
Probe for the following if they do not emerge: 
- How long have you been on BHT? 
- How was your initial response when starting BHT? 
-  How is your response to BHT now? 
-What do you like most about the BHT treatment approach? Why? 
- What do you like least about the BHT treatment approach? Why? 
 
E) Interaction with family doctor: 
1) What do you feel is the role of a family doctor with regard to a women’s menopausal 
health?   
2) Do you feel you can talk to your family doctor about your BHT use?  
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Probe for the following if they do not emerge: 
-Do you feel being on BHT has changed your interaction with him/her in some way? 
How? 
3)  What issues do you think could prevent women from discussing BHT use with their 
family doctor? 
4) What issues do you think could prevent doctors from discussing BHT use with their 
patients? 
5) How do you think the situation may be improved? 
 
Demographic information: 
As we are approaching the end of this interview I would like to ask you a few 
demographic questions  
1) How old are you?  
 
2) Are you pre or post menopausal (i.e. have you not had a period for 1year)   
If post-menopausal. 
What is your best estimate of when menopause started for you? 
___ Months &/or _____ Years ago. 
 
3) Was your menopause natural or due to a hysterectomy?  
 
 4) People living in Canada come from many different cultural and racial backgrounds.    
How would you best describe your race or color? 
INTERVIEWER: Do not read categories to respondent- Mark all that apply 
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 White  
 Chinese 
 South Asian (e.g. East Indian, 
Pakistani, Sri Lankan) 
 Black 
 Filipino 
 Latin American 
 Southeast Asian (e.g. Cambodian, 
Indonesian, Laotian, Vietnamese) 
 Arab 
 West Asian (e.g. Afghani, Iranian) 
 Japanese 
 Korean 
 Aboriginal (North American 
Indian, Metis or Inuit) 
 other (specify):_____________ 
 
5) What is the highest level of education that you have attained? 
INTERVIEWER: Do not read categories to respondent 
 no schooling  
 1-5 years 
 6 years 
 7 years 
 8 years 
 9 years 
 10 years 
 11 years 
 12 years 
 13 years 
 
 high school graduate 
 some trade, technical or vocational school 
 some community or business college 
 diploma/certificate from community college, 
CFGEP, nursing school or university 
 bachelor/undergraduate degree             
(BA,BSc,BEd, BSW, etc.) 
 masters degree (MA, MSc, MEd, MSW, etc.) 
 professional degree (medicine, dentistry, 
veterinary medicine, optometry, law) 
 earned doctorate (PhD, DSc, DEd, etc.) 
 other (specify):_______________ 
 
 
 6) What is your current marital status? Are you married, living with a partner, or common 
law, widowed, divorced, separated, or have you never been married? 
 
INTERVIEWER: Do not read categories to respondent (Check one response) 
        1  married 
        2  living with a partner/common law  
        3  widowed 
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        4  divorced   
        5  separated 
        6  never been married 
 
7) To help us describe the group of women that we've interviewed for this study, we 
would like to know the best estimate of your household income from all sources in the 
past 12 months. Which of the following is the best estimate of your household income 
from all sources in the past 12 months 
INTERVIEWER: Read categories to respondent 
 less than $5,000  
 $5,000 - $9,999 
 $10,000 - $19,999 
 $20,000 - $29,999 
 $30,000 - $39,999 
 $40,000 - $59,999 
 $60,000 - $79,999 
 $80,000 - $99,999 
 $100,000 – $119,999 
 $120,000 or more 
 I Choose Not to Answer 
 
 
Thank you for participating in this study 
 
 
 
 
 
 111 
 
 
(Appendix III ) Letter of Information and Consent for Women’s Study                                                                                             
 
Bio-Identical Hormone Therapy: Women’s Decision-Making Process and Family 
Physicians’ Views 
LETTER OF INFORMATION FOR WOMEN 
Investigators: 
Graham J. Reid, Ph.D., 
C.Psych. 
Psychology & Family Medicine, 
Western University 
Principal Investigator 
Amanda Terry, Ph.D. Family Medicine, Western University Co-Investigator 
John Jordan, MD,CCFP, 
MClSc, FCFP 
Family Medicine, Western University Co-Investigator 
Lemmese Al-watban 
MD,CCFP 
Family Medicine, Western University Co-Investigator 
Purpose: The purpose of this research project is to learn about menopausal women’s 
thoughts, feelings, attitudes and behaviours relating to their decision to use Bio-identical 
Hormone therapy (BHT). The "bio-identical" approach refers to individualized doses of 
hormones that are custom-made and compounded by a pharmacy in the form of creams, 
gels, pills, or suppositories for an individual according to a healthcare provider’s 
prescription. This is being studied so that physicians may have a better understanding of 
menopausal women’s choice to use BHT, and in turn may be able to provide them better 
care. You are being invited to participate in this research project because you are a 
woman experiencing menopause, who has received BHT. 
Procedures: If you agree to participate in this study, you will be interviewed about your 
menopausal experience, your thoughts on BHT and experience using it. 
This interview will take approximately 45-60 minutes, and take place at a location and 
time that is convenient for you. If you prefer, a telephone interview can be arranged. The 
interview will be audio -recorded.   
A separate part of this project involves interviewing family physicians. You will be asked 
if you would be willing to provide us the name of your family physician. If so, we would 
contact your family physician and invite him/her to be participant as well.  However, your 
identity would not be revealed to your family physician nor would the fact that you are 
participating in this study.  
Participant’s Initials: _______ 
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Reimbursement 
In appreciation for your time you will receive a ($10 Tim Horton’s or alternative) gift card.  
Risks and Benefits 
There are no known risks to your participation in this study. There are no known benefits 
to you personally associated with your participation in this research. The benefits of 
participating in the study include helping family physicians better understand why women 
chose to use BHT and what the experiences and decision-making of women related to 
BHT. It is hoped that this information can assist family physicians to provide better care 
to women as they experience menopause. 
Voluntary Participation: 
Participation in this study is voluntary. You may decline to participate, decline to answer 
any questions or withdraw from the study at any time.  Your current and future care at 
the Southern Ontario Fertility Technologies (S.O.F.T.) clinic will not be affected in any 
way if you chose not to participate or withdraw from the study.  
Confidentiality and Privacy: 
All information obtained for the study is confidential.  The content of the audio-recorded 
interviews will be transcribed with any identifying information removed. All participants 
will be given a study identification number (ID) and their interview data will be identified 
only by their ID number.  Identifying information such as your name will be kept separate 
from your interview.  All paper forms will be kept in a locked file cabinet at the offices of 
the researchers. All electronic files will be stored on the researchers’ computers with 
encrypted protection. Information in this study is only for research. Although we recruited 
you from the Southern Ontario Fertility Technologies (S.O.F.T) clinic, the research team 
is based at the Western University in the Department of Family Medicine. Information 
gathered for this study will not be shared with the staff at the SOFT clinic.  If you choose 
to identify your family physician, she/he would not be told about your participation in this 
study. 
 
Participant’s Initials: _______ 
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When the study results are presented or published your name or other identifying 
information will not be used.  At the end of the study, all paper documents will be 
scanned into an electronic file and the originals shredded. All the electronic data will be 
maintained for a period of 5 years after the last publication and then destroyed.  This 
study is part of a Master’s thesis for Lemmese Al-watban, MD at Western University 
Ontario. 
Representatives of Western University’s Health Sciences Research Ethics Board may 
contact you or require access to your study-related records to monitor the conduct of the 
research. 
Waiver of Rights: 
You do not waive any legal rights by signing the consent form. 
 
Contact Information: 
This letter is for you to keep.  If you have any questions about the conduct of this study 
or your rights as a participant in this research, you may contact: The Office of Research 
Ethics at (xxx) xxx-xxx or by email at xxxxxx@xxxxxx. 
If you have questions about the study itself, please contact Dr. Lemmese Alwatban at 
(xxx) xxx-xxxx or email: xxxxxxxx@xxxxxx or Dr. Graham Reid at (xxx) xxx-xxxx. 
 
Sincerely, 
 
 
Participant’s Initials: _______ 
 
Lemmese  Al-watban, MD, CCFP 
Master of Clinical Science in Family 
Medicine (MClSc) student 
 
Dr. Graham Reid, C. Psych.   
Associate Professor, Psychology, Family Medicine & 
Paediatrics 
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PARTICIPANT CONSENT FORM 
 
Bio-Identical Hormone Therapy: Women’s Decision-Making Process and Family 
Physicians’ Views 
 
I have read the Letter of Information, have had the nature of the study explained to me, 
and I agree to participate. All questions have been answered to my satisfaction.  
 
______________________________________ _______________ 
Signature                                                                                            Date 
______________________________________ 
Printed Name 
 
Witness:  
______________________________________ _______________ 
Signature                                                                                            Date 
______________________________________ 
Printed Name 
 
 
 Verbal agreement prior to telephone interview 
Signature: _______________________________   Date: ___________________ 
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(Appendix IV )Letter of Invitation for Family Physician Study  
 
Dear <<Physician’s Name>>, 
Researchers from The Centre for Studies in Family Medicine at Western University 
are interviewing family physicians in Southwest Ontario who provide primary care to 
menopausal women. They are interested in exploring family physicians’ perceptions 
and thoughts about Bio-identical Hormone Therapy (BHT) and their experiences with 
patients on this treatment modality. The results will help them better understand why 
women chose to use BHT, and how that choice might impact the patient-doctor 
relationship. 
The study, entitled ‘Bio-Identical Hormone Therapy: Women’s Decision-Making 
Process and Family Physicians’ Views’ involves an interview that will take 
approximately 30 minutes, and take place at a location and time that is convenient for 
you; a telephone interview may be arranged if you prefer.  You will be asked to 
respond to a series of questions about: Your thoughts on BHT, the role a family 
doctor plays in managing menopausal women’s symptoms and your experience in 
caring for women on BHT. 
Participation in this study is voluntary. You may decline to participate, decline to 
answer any questions or withdraw from the study at any time. 
 Dr. Al-watban will contact you by telephone within the next week to answer any 
questions and schedule an interview if you are interested in participating. 
Alternatively, you are welcome to contact Dr. Lemmese Al-watban at (xxx) xxx-xxxx 
or email her at xxxxxx@xxxxx or Dr. Graham Reid at (xxx) xxx-xxxx, to discuss the 
study. 
Thank you for considering participating in this study  
Sincerely, 
 
 
Lemmese  Al-watban, MD, CCFP 
Master of Clinical Science in Family Medicine 
(MClSc) student 
Dr. Graham Reid, C. Psych.   
Associate Professor, Psychology, Family 
Medicine & Paediatrics 
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(Appendix V ) Letter of Information and Consent for Family Physician Study  
Bio-Identical Hormone Therapy: Women’s Decision-Making Process and Family 
Physicians’ Views 
LETTER OF INFORMATION FOR FAMILY PHYSICIANS 
Investigators: 
Graham J. Reid, 
Ph.D.C.Psych. 
Psychology & Family Medicine, 
Western University 
Principal Investigator 
Amanda Terry, Ph.D. Family Medicine, Western University Co-Investigator 
John Jordan, MD,CCFP,  
MClSc, FCFP 
Family Medicine, Western University Co-Investigator 
Lemmese Al-watban 
MD,CCFP 
Family Medicine, Western University Co-Investigator 
Purpose: The purpose of the research project is to explore Southwest Ontario practicing 
family physicians’ perceptions and attitudes with regard to Bio-identical Hormone 
Therapy (BHT), and their experiences with patients on this treatment modality.  The "bio-
identical" approach refers to individualized doses of hormones that are custom-made 
and compounded by a pharmacy in the form of creams, gels, pills, or suppositories for an 
individual according to a healthcare provider’s prescription.  We seek to better 
understand why women chose to use BHT and how that choice might impact the patient-
physician relationship.  
You are being invited to participate in this research project for one of the following 
reasons: 
1) A patient who participated in an interview is part of the study identified you as her 
family physician.  
2) Another family physician who participated in this study suggested we contact you. 
3) You are a family physician practicing in southwestern Ontario. 
Procedures: If you agree to participate in this study, you will be interviewed about your 
thoughts on BHT, the role a family physician plays in managing menopausal women’s 
symptoms and your experience in caring for women on BHT. This interview will take 
approximately 30 minutes, and take place at a location and time of your choice. If you 
prefer, a telephone interview can be arranged. The interview will be audio-recorded.  
        Participant’s Initials: _______ 
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Reimbursement 
In appreciation for your time you will receive a ($10 Tim Horton’s or alternative) gift card.  
Risks and Benefits 
There are no known risks to your participation in this study. There are no known benefits 
to you personally associated with your participation in this research. The information 
gathered in this study will provide family physicians a better understanding about why 
women chose to use Bio-identical hormones and how that choice might impact the 
patient-physician relationship. It is hoped that information can assist family physicians to 
provide better care to women as they experience menopause. 
Voluntary Participation: 
Participation in this study is voluntary. You may decline to participate, decline to answer 
any questions or withdraw from the study at any time.  
Confidentiality and Privacy: 
All information obtained for the study is confidential.  The content of the audio-recorded 
interviews will be transcribed with any identifying information removed. All participants 
will be given a study identification number (ID) and their interview data will be identified 
only by their ID number.  Identifying information such as your name will be kept separate 
from your interview.  All paper forms will be kept in a locked file cabinet at the offices of 
the researchers. All electronic files will be stored on the researchers’ computers with 
encrypted protection. Information in this study is only for research.  When the study 
results are presented or published, your name or any other identifying information will not 
be used.  At the end of the study, all paper documents will be scanned into an electronic 
file and the originals shredded. All the electronic data will be maintained for a period of 5 
years after the last publication and then destroyed.  
This study is part of a Master’s thesis for Lemmese Al-watban, MD at Western 
University. 
Representatives of Western University’s Health Sciences Research Ethics Board may 
contact you or require access to your study-related records to monitor the conduct of the 
research. 
 
Participant’s Initials: _______ 
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Waiver of Rights: 
You do not waive any legal rights by signing the consent form. 
 
Contact Information: 
 
This letter is for you to keep.  If you have any questions about the conduct of this study 
or your rights as a participant in this research, you may contact: The Office of Research 
Ethics at (xxx) xxx-xxxxx or by email at xxxxxx@xxxxxx. 
 
If you have questions about the study itself, please contact Dr Lemmese Alwatban at 
(xxx) xxx-xxxx or email: xxxxxxx@xxxxxx or Dr. Graham Reid at (xxx) xxx-xxxx. 
 
Sincerely, 
 
 
 
 
 
 
 
Participant’s Initials: _______ 
 
Lemmese  Al-watban, MD, CCFP 
Master of Clinical Science in Family Medicine 
(MClSc) student 
 
Dr. Graham Reid, C. Psych.   
Associate Professor, Psychology, Family 
Medicine & Paediatrics 
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PARTICIPANT CONSENT FORM 
Bio-Identical Hormone Therapy: Women’s Decision-Making Process and Family 
Physicians’ Views 
I have read the Letter of Information, have had the nature of the study explained to me, 
and I agree to participate. All questions have been answered to my satisfaction  
 
______________________________________ _______________ 
Signature                                                                                            Date 
______________________________________ 
Printed Name 
 
Witness:  
______________________________________ _______________ 
Signature                                                                                            Date 
______________________________________ 
Printed Name 
 
 
 Verbal agreement prior to telephone interview 
 
 
Signature: _______________________________   Date: ___________________ 
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(Appendix VI ) Interview Guideline for Family Physician Study 
 
INTERVIEW GUIDELINE: FAMILY PHYSICIANS 
 
Introduction to Interview: 
This study is about exploring family physicians’ perceptions and thoughts about Bio-
identical Hormone therapy (BHT) and their experiences with patients on this treatment 
modality. I will be asking you questions in four main areas relating to your thoughts about 
BHT, your experience caring for women on BHT, the family doctor’s role and reasons 
why women chose BHT. At the end of the interview I will ask a few demographic 
questions. The aim of the interview is to better understand your thoughts regarding BHT 
and your approach to caring for menopausal women.  
 
 
1) I would like to start by asking you to share your thoughts about Bio-identical hormone 
therapy?   
Probe for the following if they do not emerge:  
- How is it different from conventional hormone therapy? 
- What do you think about the validity of this treatment modality? 
 
2) Have you had women in your practice on BHT?  What is your experience in caring for 
them? 
Probe if the following if they do not emerge: 
- Have you experienced some challenges in their care? What are they?  
- Have you been able to overcome them? How?  If not why do you think that is? 
- Have you questioned their choice of BHT? (understanding of the reason to use it 
vs. trying to discourage them from using it) 
 
3)  Could you tell me about what you think the role of a family doctor is in managing 
women’s menopausal symptoms in general? 
Probe for the following if they do not emerge: 
- Has women’s decision to use BHT changed that role? How? Why? 
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- Does the patient-doctor relationship change? How? Why? 
 
4)  In your opinion what factors influence a woman’s decision to use BHT? 
Probe for the following if they do not emerge: 
- Do you feel you have a role in their decision making process? How? 
-  What issues do you think could prevent women from discussing BHT use with 
their family doctor? 
- What issues do you think could prevent doctors from discussing BHT use with 
their patients? 
-  How do you think the situation may be improved? 
 
Demographic information: 
 
 
-How old are you? 
-How many years have you been in practice? 
- How would you categorize your practice (Urban vs. Rural)? 
*Gender filled in by interviewer (male /female) 
 
Thank you for participating in this study 
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(Appendix VII ) Ethics Approval  
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Riyadh, Saudi Arabia  
2003-2004 
 
Medical Internship training 
King Khalid University Hospital and  King Fahad National Guard 
Hospital 
Riyadh, Saudi Arabia 
1997-2003 
 
Bachelor of Medicine and Surgery (MBBS) with Honors 
King Saud University (College Of Medicine) , 
Riyadh ,Saudi Arabia 
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Awards and Academic Distinctions
 
2009 
 
College of Family Physicians of Canada (CFPC)  Family Medicine 
Resident Award for Scholarship  
• The award recognizes the outstanding academic 
accomplishments of family medicine residents 
2006 -2013  
 
King Saud University Academic Scholarship  
King Saud University 
Riyadh, Saudi Arabia   
2007-2013 
 
King Abdullah Scholarship 
 Government of Saudi Arabia   
1997-2003 
 
King Saud University, College of Medicine Honours List 
Riyadh , Saudi Arabia  
 
 
Professional Experience 
 
2012-2013 
 
Sexual Health Unit  
Juravinski Hospital 
 Hamilton ,ON 
2012-2013 
 
Pelvic Pain Clinic  
Juravinski Hospital 
 Hamilton ,ON 
2011-2012 
 
Post Traumatic Stress Disorder Clinic and Research Unit (PTSD) 
University of Western Ontario, London Health Sciences Centre  
London ,ON 
2011-2012 
 
First Episode Mood and Anxiety Program (FEMAP) 
London Health Sciences Centre, Adult Mental Health Services 
London ,ON 
2011-2012 
Eating Disorders Program 
London Health Sciences Centre, Child and Adolescent Mental Health 
Care Program.  
London, ON 
2011-2012 
 
Regional Sexual Assault and Domestic Violence Treatment Centre 
St. Joseph’s Health Care London 
London, ON 
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2011 
 
Menopause Clinic 
Grey Nuns Community Hospital 
Edmonton, AB 
2011 
 
Osteoporosis Clinic  
Grey Nuns Community Hospital 
Edmonton, AB 
 
2011 
True Balance Institute: Health and Beauty Clinics/ Bio-identical 
Hormone therapy 
Sherwood Park, AB 
2010-2011 
 
St. Joseph's Family Medical and Dental Centre 
London, On 
2009-2010 
 
Meadowbrook Medical Clinic 
Edmonton, AB 
2007-2009 
 
Meadowlark Family Clinic and Health Centre  
Edmonton, AB 
2005-2006 
 
Family Medicine Clinics  
King Khalid University Hospital 
Riyadh, Saudi Arabia  
 
 
Academic and Teaching Experience
 
2012-2013 
 
Supervising and Teaching Gynecology/ Obstetric Residents  
Sexual Health Care unit 
Hamilton, ON 
2012-2013 
 
Review of manuscripts  for the Journal of Clinical Rheumatology   
 
2013 
 
Presentation, Scleroderma Society of Ontario 
“Scleroderma and Sexuality” 
Mississauga, ON 
2013 
 
SOO Examiner for the Collage of Family Physicians of Canada   
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2010-2011 
Development and Delivery of  Family Medicine Resident group  
sessions: 
“Mood disorders” “ Antidepressant Therapy” and “Women's Sexual 
Health” 
St. Joseph's Family Medical and Dental Centre 
London, On 
2008 
 
Participant with the Family Medicine Resident Recruitment 
Committee  
University of Alberta  
Edmonton , AB 
2005-2006 
 
Demonstrator in the Department of Family and Community 
Medicine  
• Responsibilities: Lecturer, “Medical Ethics Course” 
• Supervisor for undergraduate medical trainees’ presentations 
and research activities 
King Saud University  
Riyadh, Saudi Arabia  
 
2001 
 
Organizer with the Committee for Acceptance and Enrolment at 
King Saud University Unified Health Colleges Recruitment 
Program 
King Saud University  
Riyadh, Saudi Arabia 
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